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iii. Abstract   
 
Benefits are measurable improvements that result from project outcomes. There is an emphasis 
in clinical trials literature that clinical trial benefits must always outweigh the risks yet there is 
limited clarity on processes to manage and ensure delivery of those benefits. With uncertainty 
around the delivery of clinical trial benefits, it is worth adopting a balanced management 
approach. This study looked to establish whether there were any comprehensive benefits 
management processes in HIV clinical trials and compared these practices to those described in 
the literature.  
 
Methods: To assess the current benefits management practices used to manage HIV clinical 
trials, a cross-sectional study used a critical review of clinical trials guidelines and publications as 
well as an online survey that was distributed to stakeholders in clinical trials management.   
 
Results: The critical review of the guidelines and literature revealed a high emphasis on risk-
benefit assessment, but very limited mention of the processes used for the assessment and 
management of those risks and benefits. The diverse group of clinical trials managers that 
responded to the online survey were involved at the strategic level of their respective clinical 
trials and 74% of them had never heard of Benefits Realization Management (BRM) and BRM 
processes. The respondents however, acknowledged that their lack of awareness did not 
necessarily mean lack of existence of BRM or BRM processes in HIV clinical trials. There were 
aspects of benefits management practices in clinical trials that were found to be similar to those 
in literature and other industries such as benefits planning, benefits identification, benefits 
review, setting time scale to benefits realization and allocating benefits champions. Even though 
there was confidence from the respondents in how clinical trial benefits were managed and in 
clinical trials delivering their promise, the respondents still believed there was room for 
improvement in the current BRM processes. 
 
Conclusion: BRM processes are not readily visible or documented in HIV clinical trials. There is a 
management bias towards safety and ethics in clinical trials which seems to have resulted in 
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limited focus on benefits management. Compared to other industries, there appears to be more 
room and opportunity to implement published BRM processes. The findings from this study will 
serve as a starting point for future studies on how BRM can be incorporated into current 
management practices in order to achieve the most out of clinical trials.  
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1.1 Summary  
 
Clinical trials are initiated to test a drug or treatment regimen that is in the research and 
development stage. The treatment or regimen is intended to improve the quality of people’s lives 
or improve the current treatments towards some ailment. The managers of clinical trials should 
then keep a close eye on the strategic reasons for conducting the clinical trial throughout all 
phases of clinical trials. 
 
There is plenty of uncertainty that comes with any research. Clinical research specifically impacts 
people’s lives. It is thus worthwhile strengthening management styles to focus the clinical 
research efforts and improve the chances of positive outcomes. There has to be a balanced 
approach in managing strategic goals and the day to day issues such as enrolling a significant 
number of people, issuing the drug/intervention and collecting data to guarantee delivery of 
value or benefit.  
 
This research dissertation reports on a cross-sectional assessment of current practices and 
processes used for managing HIV clinical trials. The study looked into project management 
processes used in managing HIV clinical trials with specific focus on benefits realization 
management (BRM). This study attempted to establish any awareness or application BRM 
frameworks within the HIV clinical trials as proposed in literature. This was done by reviewing 
documented guidelines on running and managing clinical trials as well as getting individuals 
involved in the management of clinical trials to complete an online survey. The findings from this 
study will help in the improvement of BRM processes in clinical trials or serve as a guideline on 






1.2 Background  
 
Clinical trials are set up to test and collect data on experimental interventions such as new 
vaccines, drugs or therapies (Mahan, 2014; Ioannidis, 2016). The central objectives of clinical 
research is to develop generalizable knowledge and to improve and understand human health 
(Emanuel, 2000). To determine whether an intervention would be beneficial or detrimental to 
humans, clinical trials of one intervention are broken into several sequential phases with each 
phase meant to achieve a specific purpose in the testing of the unproven intervention (Mahan, 
2014). 
 
1.2.1 Clinical Trials  
 
A number of clinical trial phases are used to establish the effectiveness and safety of new 
interventions (Mahan, 2014; Ioannidis, 2016). Clinical trials can only be carried out after 
successful pre-clinical studies that tested the intervention in laboratories and on non-humans for 
efficacy, toxicities and pharmacokinetics (Mahan, 2014).  One intervention has to  be tested 
through five phases that require human participants with each phase testing a separate aspect 
of the intervention (Umscheid et al., 2011; Mahan, 2014). Phase I trials evaluate the safety and 
the best way to administer the treatment (Ross, 2006; Umscheid et al., 2011; Mahan, 2014). 
Phase II trials test the efficacy and effectiveness of the interventions with one group getting a 
placebo and another group getting the real intervention, that is demonstrate the ‘clinical 
promise’ (Umscheid et al., 2011; Mahan, 2014). Detailed understanding of the effectiveness of 
the treatment is established in Phase III trials also known as the “pre-marketing phase” of clinical 
trials (Mahan, 2014). When all goes well in Phase III, Phase IV trials are then conducted to 
establish the practicality of long-term usage in a “real world” setting (Umscheid et al., 2011; 
Mahan, 2014). Once approved, the main focus of the final Phase of trials, Phase V  trials, is to 
determine integration of a new therapy into wide spread clinical practice  (Mahan, 2014).It is 
only when phases I-IV have been completed and analyzed successfully that the intervention be 




There are ethical requirements because human beings are used as subjects (Emanuel, 2000).  
Emanuel (2000) described seven ethical requirements of clinical research that are universal and 
must be adapted in all aspects of clinical research. One of the key requirements is that the 
research must be valuable and that there must be enhancements of health or knowledge derived 
from the research (Emanuel, 2000). Another ethical requirement mentioned by Emanuel (2000) 
that complements the derived value, is that the research must have an acceptable risk-benefit 
profile. Within the context of standard clinical practice and the research protocol, risks must be 
minimized, potential benefits enhanced, and the potential benefits to individuals and knowledge 
gained for society must outweigh the risks (Emanuel, 2000).   
 
There are existing guidelines and bodies that aim to promote efficient and ethical management 
of clinical trials. These include, but are not limited to, Good clinical practice (GCP) guidelines, 
guidelines from the Declaration of Helsinki and organizations such as the Food and Drug 
Administration (FDA) (Otte et al., 2005). Investigators and research institutions such as 
universities and pharmaceutical companies, with the involvement of Institutional Review Boards 
(IRB) and Research Ethics Committees (RECs) all have specific roles in clinical research projects as 
a way to deliver impactful outcomes and add value to society as whole (Rid and Wendler, 2011). 
 
However, studies have shown inadequacies in how some clinical trials are conducted, managed 
and reported (Smyth et al., 2015). There are challenges in measuring outcome variables and 
adhering to protocols (Smyth et al., 2015). Waste across medical research (clinical or other types) 
has been estimated as consuming 85% of the billions spent in those areas each year (Macleod et 
al., 2014). It is estimated that about 1 million papers from clinical trials have been published to 
date, along with tens of thousands of systematic reviews (Ioannidis, 2016). Most of these papers 
have been deemed to be not very useful (Borgerson, 2016; Ioannidis, 2016).  
 
There is a consensus that the approach to running clinical trials requires adjustment (Macleod et 
al., 2014; Borgerson, 2016; Ioannidis, 2016). Complexity is central to management of clinical trials 
as there are multiple functions and aspects to manage. Complexity in management is a result of 
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sizeable projects that have a high degree of uncertainty, have numerous interacting elements 
and apply new methods (Vidal and Marle, 2008). In clinical trials, the complexity can come from 
the planning and design, funding, authorization, operating within regulations, monitoring and 
evaluation, public health implications to project management processes, project success factors, 
risk and close outs (Bossert et al., 2002). It is however still important that during the life cycle of 
the clinical research projects; the planned benefits are still managed regardless of the complexity. 
 
1.2.2 Benefits management  
 
If a project is adequately designed and managed, its impact should always be equal to its 
potential at the start (Hubbard, 2000). To realize the full potential of a project, it is important to 
monitor and evaluate its performance as a way to increase the value and trace reasons for any 
shortcomings (Hubbard, 2000). When designing a project plan, focus should be placed on the 
connection between project goals and the purpose behind those goals (Figure 1). An efficiently 
managed project will produce the desired outputs, the desired output will fulfil the purpose and 
the project goals will be met (Hubbard, 2000). 
 
 
Figure 1 Logical Framework used by the European Commission to evaluate efficiency, effectiveness and 
impact (adopted from Hubbard 2000). 
 
King (2000) states that there must be a reasonable chance of direct benefit from an intervention 
being studied before the possibility of direct benefit may be offered to potential subjects. 
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Without clinical trials, there is limited evidence that the experimental intervention is fully 
beneficial and the trials are a way of gathering more evidence (King, 2000).  Research is however, 
a tool to investigate the unknown and the outcomes are uncertain (Emanuel, 2000). This 
uncertainty means that a clinical trial that is efficiently managed may still not produce the desired 
outputs and therefore not fulfil the purpose (Farrell, 1998; Farrell et al., 2010). It is therefore 
hard to make any promises or give any guarantees on how efficient the intervention is and how 
long it will remain efficient without overselling through optimism bias (Chalmers and Matthews, 
2006).   
 
In most of the literature, there are three “agreed on” key types of benefits that have been 
described where clinical trials are concerned (King, 2000; Ross, 2006; Koonrungsesomboon et al., 
2016). These are: 
1. Direct benefits to subjects:  benefits that arise from receiving the intervention being studied. 
2. Collateral benefits to subjects: benefits that arise from being a subject, even if one does not 
receive the experimental intervention. For instance, these could be a free physical exam or 
free medical care. 
3. Aspiration benefits to society and future patients: these arise from the results of the study 
(King, 2000; Ross, 2006; Koonrungsesomboon et al., 2016). 
Due to the uncertainty of clinical trials, it is hard to make any guarantees on benefits (King, 2000). 
In the end, consent forms for participants in clinical trials will have strong legally tight statements 
to protect the stakeholders against unrealistic benefit expectations. Statements such as: 
 
“A reasonable chance of direct benefit exists when a reasonable person under all the 
circumstances would consider the nature, magnitude, and likelihood of direct benefit 
sufficient to reasonably choose to participate in research in anticipation of the benefit” 
 
“The prospect of direct benefit may be too small, too attenuated, too unlikely, too 




"It is not known whether your participation in this research study will have a beneficial effect." 
 
“We do not know if the benefit will occur or for how long any benefit will last” (King, 2000). 
 
Figure 2 The Cranfield Process Model for benefits management (adapted from (Ward et al., 1996)). 
 
In this work, benefit will be defined as the improvement resulting from a change (outcome) that 
is perceived as positive by one or more stakeholders (Laursen and Svejvig, 2016). The benefits of 
clinical trials can be measured in terms of lives saved, life years gained or improvements in quality 
of life (Detsky, 1989). With uncertainty around delivering clinical trial benefits, it is worth looking 
into the management processes of benefits in clinical trials. In most Information Technology (IT) 
and Information Systems (IS) projects, benefits realization management (BRM) is used to deliver 
potentials benefits (Lin and Pervan, 2003; Badewi, 2016). In IT/IS projects, BRM is defined as the 
process of organizing and managing such that potential benefits arising from the use of IT/IS, are 
actually realized (Ward et al., 1996). BRM ensures that project and programs deliver what they 
promised (Esteves and Dwivedi, 2009). It provides focus, reduces risk of failure and maximizes 
benefits achieved (Esteves and Dwivedi, 2009). Lin and Pervan (2003) highlight the usefulness of 
applying formal BRM methodologies and reviews and that different people need to be allocated 
BRM responsibility.  
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The Cranfield process model in figure 2, is commonly used in projects for delivering benefits 
(Ward et al., 1996; Lin and Pervan, 2003). It is also used for remedial action to obtain benefits 
that are being lost, and, in most cases, for identification of further benefits that could be 
uncovered as the project is running (Lin and Pervan, 2003).The model in figure 2 describes the 
five different stages of managing benefits. The first stage is the identification and structuring of 
benefits. This involves the listing and detailing of all project benefits and aligning them with 
outcomes and therefore, strategic goals (Ward et al., 1996; Serra and Kunc, 2015).  
 
Once the benefits are identified and described, the second stage of the model is the planning 
(Ward et al., 1996). A benefit realization approach requires careful planning and management 
(Ward et al., 1996). The planning focuses on the changes that will lead to the desired outcomes 
and these have to be described and documented (Serra and Kunc, 2015). The BRM processes and 
approach have to be integrated with other branches of management for a holistic approach 
(Ward et al., 1996; Lin and Pervan, 2003; Ashurst et al., 2008; Serra and Kunc, 2015).  
 
The third stage of the model focuses on the delivery of Benefits (Ward et al., 1996). Benefits are 
not automatic thus the design of the benefits realization plan and executing it will lead to the 
realization of the identified benefits (Ward et al., 1996; Ashurst et al., 2008). It is the 
implementation of the changes that will bring about the benefits (Ward et al., 1996; Laursen and 
Svejvig, 2016).  
 
The fourth stage of the model incorporates the systematic reviewing and measuring of benefits 
(Ward et al., 1996; Ashurst et al., 2008). The benefits review stage is essential because benefits 
change over the course of the project and have to be reviewed and updated (Ashurst et al., 2008). 
Benefits have to be measured to show added value and intermediate benefits (Ward et al., 1996; 
Ashurst et al., 2008).   
 
The final stage of the model focuses on further benefits exploration and application of lessons 
learned in the exploration stage (Ward et al., 1996). This involves the adoption of practices 
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required to realize the potential benefits from available information based on the organizational 
learning through monitoring and evaluation of benefits (Ward et al., 1996; Ashurst et al., 2008). 
There is a connection between BRM processes and strategy and the management  approach as 
shown in figure 3 (Mossalam and Arafa, 2016).  
 
 
Figure 3 Critical Success Factors for Benefits management (adapted from (Mossalam and Arafa, 2016). 
 
For the BRM processes in figure 2 to be successful, they have to be placed on the seven “pillars” 
of BRM as shown in figure 3. The “pillars” include:  
• Aligning benefits with strategy; 
• Starting with the end of the project in mind; 
• Utilizing successful delivery methods; 
• Integrating benefits with performance management; 
• Managing benefits from a portfolio perspective; 
• Applying effective governance; 
• And developing a value culture  (Mossalam and Arafa, 2016). 
At the project level, Mossalam and Arafa (2016) proposed a merge of the BRM processes into all 
the project management processes as shown in figure 4. These are included in the lifecycle of the 
project from initiation to the closeout. The updated processes further extend into the 
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Figure 4 Updated project management processes that include BRM processes as proposed by Mossalam 




1.2.3 Proposed Research Subject  
HIV clinical trials consist multi-disciplinary collaboration of scientists, educators and community 
members (Kublin et al., 2012; HVTN, 2017). The aim of most clinical trials is to enhance the 
discovery and facilitate the development of a safe and globally effective intervention to prevent, 
treat or cure HIV/AIDS. 
1.3 Rational for the research  
Africa is one of the centres for setting up of clinical trial sites, these trials are expensive and 
without guarantees. It is important that these clinical trials yield useful and applicable results not 
only because of the need for an HIV vaccine but also because of the risk taken by the participants 
and volunteers. Trial managers and researchers must therefore increase the chances of 
successful outcomes by using tools that will lead to realizing and sustaining planned benefits of 
clinical trials. Macleod et al. (2014) and (Borgerson, 2016) point out that alternative approaches 
to clinical trials are necessary to limit waste and to improve impacts. There is a lack of clear 
guidelines on how to achieve the effectiveness or benefits derived from clinical trials of a new 
therapy or intervention. Benefits must still be managed regardless of the uncertainty of their 
delivery. It is therefore worth exploring BRM processes in clinical trials as a means to increasing 
the likelihood of benefits realization.  
1.4 Problem statement  
 
There is an emphasis in clinical trials literature that clinical trial benefits must always outweigh 
the risks yet there is limited clarity on processes to manage and ensure benefits delivery. 
 
1.5 Research Questions  
 
The main question to address the problem statement above is:  
• Are there comprehensive benefits management processes in HIV clinical trials? 
The sub-questions are:  
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• What are the current benefit management practices in HIV clinical trials? 
• How do the current clinical trials practices compare with those described in the literature? 
1.6 Aim  
 
To explore the current processes used to manage and deliver benefits in clinical trials in spite of 




To achieve the above aim, the objectives of this study are as follows:   
• Establish the existence or absence of benefits management processes in HIV clinical 
trials. 
• Compare the HIV clinical trials BRM processes with BRM processes in the literature. 
• Propose improvements depending of existing processes by designing a concept model  
1.8 Research Design and Methods  
 
To gain an insight into the practice of benefits management in clinical trials, an inductive research 
study explored BRM and BRM processes in clinical trials. The study will be in two parts with the 
first part being a search for specific BRM processes in current guidelines of how to manage clinical 
trials. The second part of the study will be an assessment of BRM processes in practice through 
online questionnaires with individuals that hold management positions in different clinical trials. 
The two parts will therefore evaluate the regularity of application of BRM and the perception of 
its efficiency. This will be a qualitative study so once the data has been gathered, the qualitative 
data will be recorded in a coded manner that enables analysis with programs such as SPSS. 
 
1.9 Limitations  
 
Literature available on BRM is mostly on benefits in the IT/IS industry (Ward et al., 1996; Lin and 
Pervan, 2003; Love and Irani, 2004; Love et al., 2005; Ashurst et al., 2008). There is a chance that 
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the BRM processes in literature are IT/IS specific and may not be applicable in clinical research 
projects.  There is also a possibility that there is limited reporting of existing BRM in clinical trials. 
Privacy policies may restrict access to clinical trial documents and specific guidelines. Another 
challenge will be accessing the clinical trial stakeholders to participate due to the geographical 
distribution of the different clinical sites and research institutions. The number of people that 
will respond to the questionnaire will be low and should ideally be higher for a more significant 
and complete assessment and obtaining those high numbers will be challenging.  
 
1.10 Resources and costs 
 
At this time, there are no foreseeable costs that this project will require. The plan is to use the 
literature databases that the university has access to for all the literature needs. For data analysis, 



















2 Literature Review 
 
2.1 Overview  
 
This chapter is a review of the relevant literature to the research topic and provides context to 
the research problem. The review will begin with an introduction into clinical trials and health 
research projects. The sections that follow will focus on the general management of clinical trials 
as well as project management practices in clinical trials. This will lead into the final section which 
will review published work on general benefits realization management and link that with 
management practices in clinical research.    
 
2.2 Clinical trials  
 
2.2.1 What are clinical trials?   
 
Disease and human beings have always coexisted. Human beings have always been hunting for 
better ways to fight diseases be it through medicine, hygiene or diet. As newer and deadlier 
diseases emerge, human beings have to come up with interventions to combat these diseases. 
One of the tools used in the fight against diseases is clinical research and clinical trials. A clinical 
trial is a prospective study which compares the effect of an intervention with a control (Chew, 
2011). Clinical trials are set up to test and collect data on experimental interventions such as new 
vaccines, drugs, treatment strategy or therapies (Chew, 2011; Mahan, 2014; Ioannidis, 2016).  
 
The world cannot afford to not have clinical trials because the clinical trial results may help 
change current patient care practices and have an impact on community (Chew, 2011; Aghayan 
et al., 2014).  Clinical trials are the gold standard for evaluating therapies, providing the highest 
evidence for the practice of evidence-based medicine and health care reform (Chew, 2011; 
Umscheid et al., 2011; Aghayan et al., 2014). Clinical research is useful for discovering the truth 
and developing generalizable knowledge (Farrell, 1998; Emanuel, 2000; Casarett et al., 2002; 
Chew, 2011). The results can change medical dogmas and/or retire widely accepted therapies 
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that have little or no efficacy this way saving both patient lives and eliminating unnecessary costs 
(Farrell, 1998; Emanuel, 2000; Casarett et al., 2002; Chew, 2011).  
 
2.2.2 The structure of clinical trials  
 
To determine if an intervention would be beneficial or detrimental to humans, clinical trials of 
one intervention are broken into several sequential phases as shown in figure 5 with each phase 
meant to achieve a specific purpose in the testing of the unproven intervention (Mahan, 2014).  
 
Figure 5 Different phases of clinical trials (Courtesy of (Your Genome, 2017). 
 
Pre-clinical studies and Phase 0 clinical trials: are focused on testing the intervention in non-
humans for efficacy, toxicities, pharmacokinetics (Umscheid et al., 2011; Mahan, 2014). Phase I 
is the first of the phases that involve human participants. Phase I trials evaluate the safety and 
the best way to administer the treatment (Mahan, 2014). Phase II trials test the efficacy and 
effectiveness of the interventions with one group getting a placebo and another group getting 
the real intervention. The point is to demonstrate the ‘clinical promise’ (Umscheid et al., 2011; 
Mahan, 2014). Phase III trials are meant to give detailed understanding of the effectiveness of 
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the treatment. This is the “pre-marketing phase” of clinical trials (Umscheid et al., 2011; Mahan, 
2014). Phase IV trials are useful for establishing the practicality of long-term usage in a “real 
world” setting (Umscheid et al., 2011; Mahan, 2014).  
 
Once the intervention is approved, Phase V trials focus on determining the integration of a new 
therapy into wide spread clinical practice  (Mahan, 2014). Throughout each phase,  the 
participants are randomized to reduce treater-selection bias and for statistical analyses (Chew, 
2011).    
 
2.2.3 What constitutes a good clinical trial? 
 
2.2.3.1 Ethical	requirements		
A clinical trial that meets all ethical requirements and expectation is a good clinical trial. 
According to  Emanuel (2000), there are seven key universal requirements that clinical research 
studies must meet to be regarded as ethical. These are: 
(1) The research must add value by enhancements of health or knowledge. 
(2)  The research must have scientific validity.  
(3) The must be fair selection of study sites and the inclusion criteria for individual subjects must 
be fair. 
(4) The risk-benefit ratio must always be favorable. This means that the risks must be minimized, 
potential benefits enhanced, and the potential benefits to individuals and knowledge gained 
for society must outweigh the risks. 
(5) There should be an independent review of the research by unaffiliated individuals. 
(6) There should always be Informed consent by individuals who will participate in the research; 
and  
(7) There enrolled subjects should be respected, their privacy protected, given the opportunity 
to withdraw, and their well-being monitored (Emanuel, 2000).  
Other long recognized fundamental values of clinical research are nonmaleficence and 
beneficence and they ensure a favorable risk-benefit ratio (Emanuel, 2000). Beneficence as 
articulated by the National Commission for the Protection of Human Subjects in Biomedical and 
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Behavioural Research (1979) in the Belmont Report, is to maximize possible benefits and to 
minimize possible harms (Emanuel, 2000; Rid et al., 2010; Grankvist and Kimmelman, 2016; 
Koonrungsesomboon et al., 2016; Resnik, 2017). The principle of nonmaleficence states that one 
ought not to inflict harm on a person in the pursuit of benefits (Emanuel, 2000). This justifies the 
need to reasonably reduce the risks associated with clinical research (Emanuel, 2000). It would 
be pointless and unethical to continue with a clinical trial that carries more risks than benefits.   
 
Equipoise is a key ethical concept and requirement for randomized clinical trials which are great 
tools for providing impartial evidence  (Rabinstein et al., 2016; Braakhekke et al., 2017). Equipoise 
is a state of genuine uncertainty on the part of the clinical investigator regarding the comparative 
therapeutic merits between Treatment A and Treatment B in population P (Freedman, 1987; 
Rabinstein et al., 2016; Braakhekke et al., 2017). This requirement entails that the investigator 
must have no “treatment preference” throughout the course of the clinical trial (Freedman, 
1987). A randomised clinical trial can only continue if and only if, there are unknowns about how 
new Treatment B compares to Treatment A (Freedman, 1987; Rabinstein et al., 2016). Should the 
investigator discover that one treatment is of superior therapeutic merit, he or she is ethically 
obliged to offer that treatment (Freedman, 1987).   
 
If equipoise is disturbed during the trial, the trial should be stopped (Freedman, 1987). Equipoise 
is disturbed if: 
• Biological plausibility is known : if treatment is known to work, it is unethical to test it  
(Braakhekke et al., 2017) 
• Biological plausibility  is absent : When it is known that it will not work  (Braakhekke et 
al., 2017) 
• Biological plausibility is uncertain : No basis to test it, inconclusive multiple preliminary 




A good clinical trial is one that is well designed and has a solid scientific/clinical question that is 
being investigated (Farrell et al., 2010). Plans, systems, and procedures have to be in place and 
followed on a day to day basis to ensure the delivery of the desired outcome (Farrell, 1998).   
 
It is important to highlight that biased or inaccurate knowledge extracted from flawed clinical 
trials may lead to the inadvertent harm of patients (Chew, 2011; Umscheid et al., 2011). It is 
because of this potential impact of clinical trials that clinical trials are well managed and 
controlled. Once completed, it is important that the findings of the research are disseminated 
and where applicable, incorporated into clinical practice (Farrell et al., 2010). Results of a trial 
can be made widely available using a variety of media, such as articles in medical journals, online 
journals, trial registers, systematic reviews and conference presentations (Farrell et al., 2010). 
The ideal clinical trial yields findings that are applicable to clinical practice in the “real world” 
(Umscheid et al., 2011). This is known as generalizability or external validity  (Umscheid et al., 
2011). 
 
It is also important to sell the clinical trial to the public as these are the people that will volunteer 
into the trial and stand to benefit from it. A marketing approach has to be taken and applied to 
clinical trials as they have to be treated like commodities to manage and sell so that different 
stakeholders will want to participate (Francis et al., 2007; Farrell et al., 2010). It is important that 
communication channels are well set up and utilized with the many stakeholders involved in 
clinical trials (Farrell, 1998). 
 
2.2.4 What are the roles of those in clinical research? 
 
All clinical research and randomized clinical trials require multiple experts from different fields 
such as statisticians and clinicians to work together to design the best possible trial to address 
the research question (Chew, 2011). A typical clinical trial consists of: 
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• A principal investigator: This is the overall leader that designs and directs the clinical trial in 
order to achieve set goals. The overall responsibility for delivering the trial lies with the 
principal investigator (Goodarzynejad and Babamahmoodi, 2015).  
• The trial manager is responsible for day to day issues of clinical trial sites, the personnel and 
the workflow of the trial (Goodarzynejad and Babamahmoodi, 2015). Trial managers are 
responsible for ensuring that all aspects of the project are planned, implemented, monitored, 
and controlled on a daily basis, and that the project outputs and outcomes are obtained 
(Goodarzynejad and Babamahmoodi, 2015). This includes areas such as marketing, finance, 
staff issues, data collection, enrolment and development of the trial (Farrell, 1998).  Ideally, 
trial managers should be involved early on in the trial design phase, but this is rarely possible 
because of funding constraints (Farrell et al., 2010).  
• The clinical project manager is a professional who contributes project management practices 
to the clinical research to ensure that all stages of a clinical trial are properly managed. The 
project manager ensures that the objectives of the trial are achieved on time, on budget, and 
according to the GCP, and that the safety of the subjects participating in the clinical trial and 
the quality of collected data are guaranteed (Goodarzynejad and Babamahmoodi, 2015). 
• Trial Statistician provides a statistical input in the design and the data analysis (Farrell, 1998).   
• Trial secretary is in charge of key correspondence (Farrell, 1998).  
• There are many other role players in clinical trials such as the data manager, the data 
collectors, nurses and clinicians that responsible for collecting samples and conduct health 
checks on the clinical participants.  
2.2.5 Who are the beneficiaries? 
 
Patients, health care providers and the pharmaceutical industry can reap maximum benefits from 
effectively conducted clinical trials (Umscheid et al., 2011). Clinical trials for disease prevention 
often enrol a part of the population at the highest risk of developing the disease and clinical trials 
for a therapeutic intervention targets the population with the highest risk of progressing to a 
more severe stage of the disease (Chew, 2011). It is these populations that stand the biggest 
chance of benefiting from the intervention when the intervention is shown to be effective and is 
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eventually licensed. Overall, successful clinical trials are a useful tool for combating diseases and 
the general public stands to benefit from resulting disease cure and/or prevention interventions 
that results.  
 
2.3 HIV Clinical Trials  
Due to the devastating effects of HIV/AIDS on people all over the world in recent years, there 
have been many coordinated collaborative efforts to battle the disease. These come in all forms 
from scientists looking for either a vaccine or the cure to those that promote awareness and 
invent treatment regimens. An example of such a network of scientist is the HIV Vaccine Trials 
Network (HVTN). The HVTN is an international group that coordinates collaboration of scientists, 
educators and community members (Kublin et al., 2012; HVTN, 2017). The HVTN focuses on the 
discovery and development of a safe and globally effective HIV/AIDS vaccine (Kublin et al., 2012; 
HVTN, 2017). Funding is provided by public and private sources such as the U.S. National 
Institutes of Health (NIH) and the Bill & Melinda Gates Foundation (HVTN, 2017).  
The HVTN conducts all phases of clinical trials to evaluate experimental vaccines for safety and 
immunogenicity as well as testing vaccine efficacy (HVTN, 2017). The network’s clinical research 
sites are located at leading research institutions in over 30 cities on five continents and this result 
in engaging with communities and internationally renowned researchers in HIV vaccines and 
prevention (HVTN, 2017). One of the main HVTN trials that is currently taking place in South 
Africa is the HVTN 702 which is a phase 3 HIV vaccine efficacy trial (HVTN, 2017). HVTN 702 
evaluates a new version of the only HIV vaccine candidate to have shown some protection against 
HIV especially against HIV subtype that is predominant in southern Africa (HVTN, 2017).  
Since its creation in 1999, the HVTN has conducted over 50 clinical trials and results related to 
HVTN studies have been published in more than 300 manuscripts in peer-reviewed scientific 
journals (Kublin et al., 2012; HVTN, 2017). Collaborative HVTN projects have outcomes that have 
altered the vaccine design and development field moving forward (HVTN, 2017). The HVTN has 
successfully streamlined protocol development and established standardized methodologies and 
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systems allowing for reliable assessments standards across trials (Kublin et al., 2012; HVTN, 
2017). Over the past decade, the HVTN has aimed to improve the process of designing, 
implementing, and analyzing vaccine trials (HVTN, 2017). 
2.4 Management in clinical trials  
 
Clinical trials require coordinated processes and systems regardless of their size, scope, costs, or 
period (Goodarzynejad and Babamahmoodi, 2015). A clinical trial requires huge investments of 
time, money and people (Farrell et al., 2010). This means expert management is needed for 
clinical trials just like in any other business (Farrell et al., 2010). Clinical trials have many 
characteristics in common with other types of business projects. To bring about change using 
specified resources, a clinical trial like any business project has pre-defined objectives, a 
beginning and an end. All key activities are planned and executed by a team with constant 
monitoring and evaluation (Farrell et al., 2010).  A list of all the key activities of a clinical trial are 
shown in appendix C. 
 
2.4.1 Project management in clinical trials   
 
“A guide to project management body of knowledge: PMBOK guide (PMBOK)” contains a 
compilation of guidelines on project management that are published by the project management 
institute (PMI, 2013). The PMBOK defines project management as ‘the application of knowledge, 
skills, tools, techniques to a broad range of activities in order to meet requirements of a particular 
project’(PMI, 2013). Project management is used by the military, in engineering, commerce, 
industry, information systems, financial services, education and training, and health services 





Figure 6 Clinical Trial flow Process (Cao et al., 2013)  
 
There are those who have highlighted the need and application of project management in clinical 
research (Payne et al., 2011; Aghayan et al., 2014; Goodarzynejad and Babamahmoodi, 2015). 
Research is a project that can be defined as a unique and scheduled complex attempt to achieve 
specific and predefined objectives by using limited budget and resources which is usually no 
repetitive within an organization (Aghayan et al., 2014). Figure 6 shows a summary of the key 
areas that management focuses on during clinical trials (Cao et al., 2013). Trial preparation 
involves all the planning and prerequisites that need to be arranged before the clinical trial can 
resume. Recruitment of trial participants following pre-set conditions of acceptance and 
rejection, is one of the first steps in the implementation of the clinical trial (WHO, 2005). Once 
the tests and sample collections are completed, the data are analyzed and then a summary and 
reports are compiled to bring the trial to completion. 
 
Project management may benefit both the managerial and scientific aspects of medical projects 
and reduce fund waste. However, little has been written to date on project management in the 
context of clinical research (Goodarzynejad and Babamahmoodi, 2015). Like most projects, 





The main focus at this stage of a clinical trial management is on the protocol design and the 
rationale behind the trial. This is where clear objectives and aims of the trial and its specific 
outputs are defined and formulated (Aghayan et al., 2014). The key investigator will offer 
background information on the intervention (Goodarzynejad and Babamahmoodi, 2015). The 
trial has to meet all the ethical requirements set by regulatory bodies such as the IRB (Chew, 
2011). Each trial needs to develop a management blueprint setting achievable targets, 
developing an enthusiastic team and securing the time and money to make the whole process 
efficient and deliverable (Farrell, 1998).  
 
2.4.1.2 Planning 
The project plan should also describe what the stakeholders of the trial are trying to achieve, 
planned processes, how resources will be used and within what time frame (Farrell et al., 2010). 
Figure 7 shows a progress layout of a clinical trial through the enrolment, allocation, post-
allocation and close-out phases. A team with requisite knowledge and skills is organized and the 
project plan should describe who will be responsible for essential activities, communication with 
the collaborative group, recruitment monitoring, data management, and raising project 
awareness (promotion/marketing), through to safety reporting, analysis, report writing and 
dissemination of the trial results (Farrell et al., 2010; Aghayan et al., 2014). A risk management 
plan has to be part of the planning. 
 
2.4.1.3 Executing  
One of the first acts in clinical trials is the recruitment of appropriate patient/participants into 
the study (Umscheid et al., 2011). The participants are screened, randomly allocated to separate 
groups of the study depending on the study design (Schulz et al., 2010). The intervention can be 
distributed or tested on different groups with dosage or any other changes being done 
accordingly as this process continues (Goodarzynejad and Babamahmoodi, 2015).  The clinical 
observation and data collection then begins. The day to day matters of the trial are heavily 





Figure 7 Flow diagram of the progress through the phase of a parallel randomised trial as adopted from 
(Chan et al., 2013).  
2.4.1.4 Monitoring and controlling  
Constantly reviewing and adapting the project plan is crucial as a trial can be hit side-on by events 
outside its control. Sensible risk assessment, tailored quality assurance management systems and 
real-time monitoring are essential if a trial is to optimize its potential and provide reliable 
evidence (Farrell et al., 2010). The Data and Safety Monitoring Committee (DSMC) are individuals 
with varying expertise including statisticians, clinicians and clinical trialists charged with ensuring 
the safety of the participants by periodic evaluation of the data (Chew, 2011). They will also 
evaluate baseline variables, adverse effects, and response to therapy periodically (Chew, 2011).  
The DSMC makes recommendations to the study leadership for early termination of the study of 
there is unanticipated serious toxicity, greater than the expected benefits, or the likelihood of 
not finding a difference between the treatment and control group (Chew, 2011). 
 
2.4.1.5 Closure  
The trial enters the closure phase when the findings are analyzed and reported. The data is “un-
blinded” by revealing the participants that were randomly assigned and statistically analyzed to 
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compare the effects of those who received the intervention versus those who did not (Schulz et 
al., 2010). All the data and information collected is checked and queries addressed 
(Goodarzynejad and Babamahmoodi, 2015). The project is closed when the objectives have been 
achieved or when the objectives will not or cannot be met, or when the need for the project no 
longer exists(Farrell et al., 2010; Goodarzynejad and Babamahmoodi, 2015). The findings and 
summary of the clinical trial can then be reported as directed by the CONSORT 2010 guidelines 
(Schulz et al., 2010; Umscheid et al., 2011). 
 
2.4.2 Clinical Trial Management 
 
The management approach of clinical trials is not like that of standard business projects. The 
management approach is shaped and guided by set standards of several regulatory bodies. These 
industry “watchdogs” regulate and audit clinical trials from beginning to end and therefore shape 
how clinical trials are managed. These are some of the regulatory clinical trial bodies and 
practices:  
2.4.2.1 Good Clinical Practice (GCP) 
Management approach of clinical trials is mainly shaped by Good Clinical Practice (GCP) 
guidelines. GCP standards are used internationally to set the bar for ethical and scientific quality 
(Otte et al., 2005; Bongiovanni et al., 2015). Clinical researchers have to take GCP guideline when 
designing, conducting and reporting trials that involve the participation of human subjects (Otte 
et al., 2005; Bongiovanni et al., 2015). GCP was born due to the concerns that came about when 
human subjects started being used in medical research in the 1900s (Otte et al., 2005). These 
Guidelines have taken many forms an included many organizations over the years with necessary 




Figure 8 Milestones in the international development of good clinical practice (Otte et al., 2005). 
The key aspects of GCP is to: 
• protect the rights, safety, and well-being of trial subjects; 
• ensure the quality and integrity of data obtained from clinical testing (Otte et al., 2005). 
The GCP guidelines informs researchers on many other components such as how to freely 
obtain informed consent from each subject, listing safety monitoring requirements, data 
handling and archiving requirements as well as outlining clinical trial responsibilities of the 
stakeholders (Otte et al., 2005).  
 
Otte et al. (2005) highlighted and summarized the 12 golden rules of GCP as follows: 
1. Know and strictly follow the study protocol. 
2. Select, train and keep a log of all study team members. 
3. Record data correctly. 
4. Ensure adequate study equipment. 
5. Obtain ethics committee approval before starting and get the written informed consent of all 
subjects before they take part. 
6. Predict recruitment accurately and keep an up-to-date subject enrolment log. 
7. Precisely document product accountability. 
8. Report serious adverse events immediately to the sponsor. 
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9. Check laboratory sample quality and review laboratory results. 
10. Maintain good trial files and archives. 
11. Diligently collect and record reliable data. Keep all source documents. 
12. Keep everyone fully informed. 
2.4.2.2 Institutional Review Boards (IRB) 
One of the key elements of GCP is that medical researchers are only permitted to start a clinical 
trial if they obtained the approval of an Institutional Review Board (IRB) (Musschenga et al., 2007; 
Chew, 2011). The IRB is made up of at least five members  and this number usually included at 
least one member that has a non-scientific background and at least one member who is 
independent of the institution/trial site (Otte et al., 2005). The IRB evaluate the scientific quality 
of a trial by reviewing its originality, importance, feasibility, methodological soundness and 
information provided to potential research subjects (Musschenga et al., 2007). The IRB also 
review investigators capabilities and address relevant ethical concerns such as coercion or undue 
influence on the trial subjects (Otte et al., 2005). Each trial must therefore be designed and 
managed to meet IRB applicable regulatory requirements.  
 
2.4.2.3 Key documents  
Clinical Trial Protocol - A protocol is a plan that details how a clinical trial is to be carried out and 
how the data are to be collected and analysed (Chow and Liu, 2008). A list of the key details that 
are included in a clinical trial protocol are shown in appendix D. A protocol  ensures the quality 
and integrity of the clinical investigation in terms of its planning, execution, and conduct of the 
trial as well as the analysis of the data (Chow and Liu, 2008). A protocol provides details of the 
trial plans, rationale, ethics approval, administration of the trial, implementation, statistical 
analyses, dissemination of results, interpretation and external review (Chan et al., 2013). The 
details in the protocol will influence how the report is written at all times (Al-Marzouki et al., 
2008).  
Standard operating procedures (SOPs) – A SOP is a document of standardized working procedures 
for all functions (including the initiation, conduct, and reporting of clinical trials) implemented 
throughout the specific research unit organization in order to ensure accurate and reliable data 
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(Bairu and Chin, 2012). The concept of standardizing procedures (SOPs) was first developed in 
the manufacturing sector to ensure that products conform to specifications  and standards and 
to eliminate batch to batch variability; it was later adopted by most industries (Bairu and Chin, 
2012). SOPs are mandatory in all clinical research settings, including pharmaceutical companies, 
regulatory authorities, ethics committees and laboratories, (Bairu and Chin, 2012). SOPs assign 
responsibility to components of a process, SOPs act as step-by-step instructions for the training 
of new and temporary staff (Bairu and Chin, 2012).  
 
Policies document the attitudes, norms, and expectations of an organization towards specific 
concepts, such as behaviour in the workplace, dress code and work-related travel (Bairu and Chin, 
2012). Policies do not include procedures and do not necessarily assign responsibilities to specific 
positions (Bairu and Chin, 2012). 
 
Guidelines are significantly more detailed than SOPs and are less stringently controlled. They are 
synonymous with regulations in a legal framework (Bairu and Chin, 2012). Guidelines contain 
wisdom that advises, in situations where prescribing is too restrictive (Bairu and Chin, 2012). An 
organization cannot be cited in an audit for not adhering to each element within a guideline 
(Bairu and Chin, 2012). Guidelines typically include details that improve quality but are not 
essential to meet regulatory requirements (Bairu and Chin, 2012). 
 
2.4.2.4 Reporting 
There are guidelines and requirements on the format and content of clinical trial reports and 
publications. This is to ensure that the reports cover all the key aspects of the clinical trial. There 
are several recommended formats for clinical trial publications but the most commonly used is 
the CONSORT Statement guidelines (Schulz et al., 2010; Umscheid et al., 2011). The CONSORT 
(Consolidated Standards of Reporting Trials) statement is a 25 items checklist guideline on 
information to include when reporting randomized controlled trials worldwide as shown on table 
1 (Schulz et al., 2010; Umscheid et al., 2011). The CONSORT statement improves accessibility of 
clinical results to those in the position to use them (Schulz et al., 2010; Umscheid et al., 2011). 
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The CONSORT statement offers a layout that allows for an accurate assessment of a trial by 
readers of a published report as the report will be complete, clear, and transparent information 
on its methodology and findings (Schulz et al., 2010). 
 
An alternative to the CONSORT statement is the SPIRIT Statement (Chan et al., 2013). The SPIRIT 
(Standard Protocol Items: Recommendations for Interventional Trials) 2013 Statement is a 33-
item checklist for all clinical trials that focuses on content rather than format (Chan et al., 2013). 
The checklist recommends a full description of what is planned; it does not prescribe how to 
design or conduct a trial (Chan et al., 2013). Adherence to SPIRIT enhances transparency and 
completeness of trial protocols for the benefit of investigators, trial participants, patients, 
sponsors, funders, research ethics committees or institutional review boards, peer reviewers, 
journals, trial registries, policymakers, regulators, and other key stakeholders (Chan et al., 2013). 
There are a lot similarities between the SPIRIT Statement and the CONSORT Statement but their 
overall aim to promote diligent adherence by authors to the checklist items to facilitates clarity, 
completeness, and transparency of reporting (Schulz et al., 2010). 
 
2.4.2.5 Peer review 
The established practice for evaluating science and research is through the peer review process 
(Barke, 2009). The peer review is done by experts and sometimes research committees (Barke, 
2009). The US Department of Health and Human Services has stated that If data and analytic 
results have been subjected to formal, independent, external peer review, the information may 










Table 1 CONSORT 2010 publication checklist Randomized Trial (Schulz et al., 2010) 
Section/Topic Item Checklist Item Reported on Page No 




Identification as a randomized trial in the title 
Structured summary of trial design, methods, results, and conclusions (for specific 





Background and objectives 
2a 
2b 
Scientific background and explanation of rationale 






























Description of trial design (such as parallel, factorial) including allocation ratio 
Important changes to methods after trial commencement (such as eligibility 
criteria), with reasons 
Eligibility criteria for participants 
Settings and locations where the data were collected 
The interventions for each group with sufficient details to allow 
replication, including how and when they were actually administered 
Completely defined pre-specified primary and secondary outcome 
measures, including how and when they were assessed 
Any changes to trial outcomes after the trial commenced, with reasons 
How sample size was determined 









































Method used to generate the random allocation sequence 
Type of randomization; details of any restriction (such as blocking and block size) 
Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any steps taken 
to conceal the sequence until interventions were assigned 
Who generated the random allocation sequence, who enrolled participants, and 
who assigned participants to interventions 
If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
If relevant, description of the similarity of interventions  
Statistical methods used to compare groups for primary and secondary outcomes 


















Participant flow (a diagram 
































For each group, the numbers of participants who were randomly assigned, 
received intended treatment, and were analysed for the primary outcome 
For each group, losses and exclusions after randomization, together with reasons 
Dates defining the periods of recruitment and follow-up 
Why the trial ended or was stopped 
A table showing baseline demographic and clinical characteristics for each group 
For each group, number of participants (denominator) included in each analysis 
and whether the analysis was by original assigned groups  
For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% confidence interval) 
For binary outcomes, presentation of both absolute and relative effect sizes 
is recommended 
Results of any other analyses performed, including subgroup analyses and 
adjusted analyses, distinguishing pre-specified from exploratory 
All-important harms or unintended effects in each group (for specific guidance 
































Trial limitations, addressing sources of potential bias, imprecision, and, if 
relevant, multiplicity of analyses 
Generalizability (external validity, applicability) of the trial findings 
Interpretation consistent with results, balancing benefits and harms, 
















Registration number and name of trial registry 
Where the full trial protocol can be accessed, if available 







2.4.3 Limitations in Managing Clinical Trials 
 
Managing clinical trials, of regardless of size requires efficient management (Farrell et al., 2010). 
There are different categories of complexity that managers of clinical trials have to take into 
consideration. For this work, the CONSORT statement is used as a snapshot of the key areas of 
focus for management in clinical trials (highlighted in table 1). These important parts of the trial 
give rise to complexity. Complexity arises from recruiting large patient sample sizes, managing 
multisite teams, inclusion or exclusion criteria, scheduling, collaborations and the 
unpredictability of clinical outcomes (Bossert et al., 2002). More of complexity in clinical research 
is due to the involvement of numerous stakeholders which include sponsors, scientists, staff, 
project managers, ethics committees, regulatory authorities, research subjects, and some others 
(Aghayan et al., 2014). This is where project management tools become applicable and useful. 
 
Many clinical trials fail to deliver because of the lack of a structured, practical, administrative and 
business-like approach to trial management (Farrell, 1998; Farrell et al., 2010; Aghayan et al., 
2014).  A sound scientific basis and a well-structured protocol can answer clinical questions but 
in the presence of inept management, successful delivery of a trial is unlikely (Farrell et al., 2010; 
Goodarzynejad and Babamahmoodi, 2015). The GCP only controls and rules scientific 
experimentation, leaves unaddressed most management issues (Bongiovanni et al., 2015). Most 
clinical researchers have limited training in project management (Payne et al., 2011). This training 
could assist in avoiding problems that may arise during research projects such as budget over-
runs, missed deadlines and problems with stakeholders (Payne et al., 2011).  
 
There is also little published information describing the use of project management health and 
medical research projects (Payne et al., 2011; Aghayan et al., 2014). There is also a skills transfer 
flaw in that project management processes are not transferred from project to project 
(Bongiovanni et al., 2015). Lessons learned are not passed on and therefore most trials have to 
design management processes from scratch (Farrell, 1998). A more business-like approach has 
to be taken for the management of clinical trial projects whereby effective management systems 
and techniques are established and implemented (Farrell et al., 2010; Goodarzynejad and 
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Babamahmoodi, 2015). Most of the literature on how to conduct or manage clinical trials is 
focused on the implementation and the day to day of all the moving parts that go into a clinical 
trial. Hagino (1991) offered guidance on how to write protocols, manage the budget and other 
administrative aspects of clinical trial. Farrell et al. (2010) attempted to offer a standardized 
managing clinical trials approach and even then, the focus was more on the efficient running of 
the moving pieces such as planning, recruitment, communications, collaborations and reporting.   
 
2.4.4 Recommendations to resolve the management issues  
 
2.4.4.1 Acquiring project management skills 
Medical and healthcare professionals need to learn project management skills, and adopt them 
for the field of health and medicine (Aghayan et al., 2014; Goodarzynejad and Babamahmoodi, 
2015). Payne et al. (2011) recommended the use of project management as it has been shown 
to increase the effectiveness of health and medical research projects as well as communication 
and teamwork within those projects. A trained clinical project manager would apply project 
management principles to clinical research to ensure that all stages of a clinical trial are properly 
managed, that the objectives of the trial are achieved on time, on budget, and according to the 
GCP, and that the safety of the subjects participating in the clinical trial and the quality of 
collected data are guaranteed (Goodarzynejad and Babamahmoodi, 2015). 
 
2.4.4.2 Portfolio Management Approach  
For one intervention to be licensed, it has to be tested at all the different clinical trial phases and 
an arguably one phase can be considered to be a separate project. The objectives and outputs of 
a Phase I trial are different to that of a Phase III trial but collectively the end goal is the same. 
Bossert et al. (2002) recommended the use of systems approach for trials with multisite research 
where a system is more than the sum of its parts and that it functions as a whole. This would 
mean each phase would still have to be managed as a singular project using project management 
principles but collectively, the phases should be managed under one programme or even as a 
portfolio. Portfolio management is  the centralized management of one or more portfolios, which 
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includes identifying, prioritizing, authorizing, managing, and controlling projects, programs, and 
other related works, to achieve specific strategic objectives (Aghayan et al., 2014).  
 
In healthcare system including health research many projects fail because of poor portfolio 
management (Aghayan et al., 2014). Aghayan et al. (2014) recommends that clinical trials should 
have a Project Management Office (PMO) to increase the capability of clinical trials. PMO 
optimizes resource allocation and processes such as standardization, monitoring, auditing and 
data management (Aghayan et al., 2014). PMO can help researchers to increase the efficiency of 
clinical studies by centralizing and consolidating of projects (Aghayan et al., 2014). The use of 
portfolio management within a PMO ensures the best performance of its programs and projects 
by efficiently using resources and obtaining favourable outcomes that are impactful on health 
and medicine (Aghayan et al., 2014).  
 
All the above-mentioned project management principles will increase the chances that the 
clinical trials deliver their intended outcomes. The research will finish on time, within budget and 
with all the phases efficiently managed. The question then becomes, have the outcomes of the 
efficiently managed clinical research project brought about the desired purpose?  
 
2.5 Benefits management  
 
A well-managed research project could turn out to not have added the intended value to the 
intended stakeholders. A successful clinical trial has to run according to all the clinical trial 
guidelines and requirements but most importantly, the outcomes of clinical trials need to be 
clinically meaningful (Chew, 2011). How then do the investigators and managers ensure that the 
clinical trial fulfils its intended clinical purpose?  
 
2.5.1 What are benefits? 
 
At the beginning of every project or programme, a project owner’s vision of a new desired state 
has to be clearly documented in the business case (Mossalam and Arafa, 2016). Projects are then 
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designed and used as tools to move from one state to the desired state hence closing the gap as 
shown in figure 9 (Serra and Kunc, 2015). At the end of each project life cycle, there are outcomes 
that result as part of the intended objectives of the project.  It is these outcomes that bring about 
desired changes that result in positive strategic improvements known as benefits (Peppard et al., 
2007; Serra and Kunc, 2015). 
 
Figure 9 Benefits close the value gap. From (Serra and Kunc, 2015). 
 
Benefits are measurable improvements resulting from outcomes (Sapountzis, 2013). Figure 10 
shows the connections between outputs, change, benefits and strategic objectives.  Project 
outputs bring about changes and these changes lead to benefits realization (Sapountzis, 2013). 
 
Figure 10 The relationship between project outputs, changes, benefits and strategic objectives 
(Sapountzis, 2013). 
 
For projects and programmes to be regarded as successful, it is important that benefits are 
measured and confirmed (Sapountzis, 2013).  The first step is for the organization is to move 
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away from an output focused style of management to a benefit orientated style of management 
(Chih and Zwikael, 2015). Output focused management is focused on managing inputs and 
outputs with the project objectives set on meeting agreed efficiency targets and the performance 
evaluation is on the iron triangle (time, budget and quality) (Chih and Zwikael, 2015). Benefit-
oriented project management involves managing inputs and outputs with a focus on the ultimate 
realization of project benefits (Chih and Zwikael, 2015). When evaluating performance, it is 
important to make the distinction between project success and project management success 
(Chih and Zwikael, 2015). Project success is measured using time, cost or quality (Chih and 
Zwikael, 2015). Project success on the other hand, is measured by benefit realization (Chih and 
Zwikael, 2015).  
 
“A successfully managed project is not the same as successful project (Mossalam and Arafa, 
2016)”. 
2.5.2 Benefits realization management  
 
In IT projects, Benefits Realization Management (BRM) is defined as the process of organizing 
and managing such that potential benefits arising from the use of IT, are actually realized (Ward 
et al., 1996). BRM aims to bridge link between defined strategic benefits and project/programme 
management  (Kagioglou and Tzortzopoulos, 2016). BRM is a process for the optimization or 
maximization of benefits from organizational change programmes (Sapountzis, 2013). BRM and 
its methodologies ensures that project and programs deliver what they promised (Lin and Pervan, 
2003; Esteves and Dwivedi, 2009; Badewi, 2016). BRM can also be used to obtain benefits that 
are being lost and for identification of further benefits that could be discovered as the project is 
running (Lin and Pervan, 2003). Poor benefit management or the complete lack of it can be the 
cause of programme failure (Sapountzis, 2013).  
 
There are numerous BRM frameworks in the literature that are proposed for realizing and 
assessing benefits (Divendal, 2011; Love et al., 2014; Breese et al., 2015). Some of these are: 
• Active Benefits Management (ABM)(Leyton, 1995). 
• The Cranfield process model of Benefits Management (Ward et al., 1996). 
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• Benefits Management Approach (BRA) (Thorp, 1999)  
• Process of Active Benefits Realization  (Remenyi and Sherwood-Smith, 1998) 
• The ABR Approach (Lin and Pervan, 2003) 
• Towards Best Practice in Benefits Management (Ashurst and Doherty, 2003). 
• Benefits Realization Management in managing successful Programmes (Bradley, 2006)  
• Benefits Realization Capability Model (Ashurst et al., 2008) 
• Benefits Management in the handbook of Programme Management (Reiss et al., 2006)  
The Cranfield process model, shown in figure 2, appears to be the most applied BRM framework 
for delivering benefits and it is the preferred model for this work (Ward et al., 1996; Lin and 
Pervan, 2003). These are the stages as they appear on the Cranfield model in figure 2.   
 
2.5.2.1 Identifying	benefits	
 Successful programmes tend to have well defined benefits that are without any vagueness 
(Sapountzis, 2013). Project benefits have to be well detailed and tied to outcomes that are 
aligned with the strategic goals (Ward et al., 1996; Serra and Kunc, 2015). According to Chih and 
Zwikael (2015), there are seven criteria to consider when formulating target benefits and these 
are: 
1. Strategic fit: the benefits have to align with the organization's overall strategy. 
2. Target value: Each benefit has to have a baseline that will be used as a starting point when 
evaluating the benefit.  
3. Measurability: The benefits must be measurable through the use of either a direct measure 
or an indirect indicator. 
4. Realism:  The benefits must be realistic, given the context in which the organization is 
operating and its constraints. 
5. Target date: There has to be a set date for each benefit to be realized. 
6. Accountability: for tracking purposes, each benefit must have an owner.   
7. Comprehensiveness: the effects of each benefit must be analyzed from variety of aspects, be 
it operational, tactical and strategic level (Chih and Zwikael, 2015). 
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Benefits can be classified into tangible and intangible (Murphy and Simon, 2002). Tangible 
benefits are those improvements that can be measured by an objective and quantitative measure 
(Murphy and Simon, 2002).  Intangible benefits however, are difficult to quantify and can only be 
judged subjectively and employ qualitative measures (Farbey et al., 1999; Murphy and Simon, 
2002; Love et al., 2005; Ward and Daniel, 2006; Sapountzis, 2013). A tangible benefit for a clinical 
intervention would be years of healthy living added on and an intangible benefit would be the 
patient’s confidence that the intervention will work. In IT project benefits can further be classified 
into several categories depending on the division the benefits impact. These categories and 
examples of each are shown in table 2. 
 




1.1 Cost reduction, 
1.2 Cycle time reduction, 
1.3 Productivity improvement, 
1.4 Quality improvement, 
2. Managerial 
 
2.1 Better resource management, 
2.2 Improved decision making and planning 
2.3 Performance improvement 
3. Strategic 
 
3.1 Support growth 
3.2 Construct innovations 
3.3 Generate product differentiation 
3.4 Build external linkages  
4. IT Infrastructure 
 
4.1 build business flexibility for current and future changes 
4.2 Increased data management capability 
5. Organizational 
 
5.1 Support organizational changes 
5.2 Facilitate organizational learning 
5.3 Empowerment 
5.4 Built common visions  
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2.5.2.2 Benefits planning 
Once the benefits are identified and described, a benefit realization approach requires careful 
planning and management (Ward et al., 1996). Benefits should be planned at the beginning of 
the project and not at the end with the path from investment to benefit delivery effectively 
outlined (Sapountzis, 2013; Mossalam and Arafa, 2016). The changes that will lead to the desired 
outcomes have to be described, documented and communicated to all the relevant stakeholders 
(Ward et al., 1996; Lin and Pervan, 2003; Serra and Kunc, 2015). The BRM plan has to be 
integrated with other branches of management for a holistic approach (Ward et al., 1996; Lin 
and Pervan, 2003; Ashurst et al., 2008; Serra and Kunc, 2015). 
 
2.5.2.3 Benefits delivery 
Benefits are not automatic and therefore it takes a well-designed benefits realization plan and 
great execution of that plan for their realization (Ward et al., 1996; Ashurst et al., 2008). A joint  
effort  from the programme director, the project manager, the change manager and the benefits 
manager will bring about the changes that will deliver the benefits plan (Mossalam and Arafa, 
2016). There are also unplanned benefits that may emerge as a result of the implemented 
changes or as a result of achieving primary benefits (Casarett et al., 2002; Ashurst and Doherty, 
2003; Sapountzis, 2013). 
 
2.5.2.4 Benefits Review 
During the life of a programme, the ability to deliver benefits may be affected by changes and 
unanticipated circumstances. These changes can come from within the programmes themselves 
or from environmental changes that affect the value of the benefits (Sapountzis, 2013). Benefits 
are measured in a systematic manner to show that added value (Ashurst et al., 2008).  Benefits 
can often be considered during the early stages of projects and tend to be forgotten and are not 
actively managed during the later stages (Ashurst et al., 2008).It is therefore important that 
planned benefits have to be monitored so that they are not lost as the project continues 
(Sapountzis, 2013). New or intermediate benefits may also arise over the course of the project 




2.5.2.5 Benefits exploration 
The practices required to realize the potential benefits from available information have to be 
adopted into the organizations way of doing things moving forward (Ward et al., 1996). This 
requires organizational learning through monitoring and evaluation of benefits (Ward et al., 
1996; Ashurst et al., 2008). This could in turn lead to finding additional benefits from the current 
and related projects (Ashurst et al., 2008). 
 
2.5.3 Role of BRM in general management 
 
BRM is linked and connected to other management disciplines as shown in figure 11 (Breese, 
2012). BRM has become very central to project, programme and portfolio management (Breese, 
2012). Every project has to have a strategy on what has to be achieved and this has to be aligned 
with the available capability. Effectively bringing about the right changes leads to the intended 
benefits being realized. 
 
Governance and Strategy: To realize benefits, changes have to happen from the top through 
effective governance.  To “govern” is to have a controlling influence on, to have a direct effect 
on, or to fix or decide (Bekker and Steyn, 2008). Project governance is a set of management 
systems, rules, protocols, relationships and structures that provide the framework within which 
decisions are made for project development and implementation to achieve the intended 
business or strategic motivation (Bekker and Steyn, 2008).  
 
The most important link of BRM to general management of projects is that the benefits must be 
aligned with the strategy (Sapountzis, 2013; Mossalam and Arafa, 2016). It is important to start 
any project or programme with the end in mind, this way, the changes and the resulting 
outcomes are related to strategic objectives (Sapountzis, 2013; Mossalam and Arafa, 2016). 
Effective project governance is an important catalyst for the development and leadership of a 
benefit management process in projects (ul Musawir et al., 2017). Although the interaction 
between project governance and benefit management process is more complex than a simple 
cause-and-effect relationship, project governance creates the roles, responsibilities, and 
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accountabilities that enable benefit management (ul Musawir et al., 2017). Project governance 
is effective in improving project success and supporting organizational strategy if key governance 
roles adopt a benefits-oriented approach (ul Musawir et al., 2017).  Reasoning for initiating a 
project and  justification for the required investments is usually stated in business case which is 
a tool that supports planning and decision making (Divendal, 2011).  A business case can ensure 
commitment from managers by describing the changes that will deliver the identified benefits 
and demonstrating a basis for the actually delivery of those benefits (Divendal, 2011). 
 
 
Figure 11 Interaction  between several management disciplines  and  BRM (Love et al., 2014).  
 
Change management: Change management is essential and central to BRM as benefits do not 
simply occur through the insertion of changes within organizational processes (Sapountzis, 2013). 
Benefits arise when the people in the organizations embrace the changes in their business 
processes (Sapountzis, 2013). Previous studies highlight the importance of essential 







projects (Doherty et al., 2012). Some of these changes include utilizing successful delivery 
methods such as programme management (Mossalam and Arafa, 2016). 
 
Programme management: Programmes themselves rarely deliver benefits directly, but by 
combining projects and their deliverables to create the capabilities that enable the desired 
benefits to be achieved (Sapountzis, 2013). The benefits of each project can only be derived when 
combined with outcome of other projects (Sapountzis, 2013). 
 
Performance management: By developing a benefits culture, BRM creates a system where 
continuous evaluation ensures that the processes deliver benefits (Sapountzis, 2013; Mossalam 
and Arafa, 2016). This culture influences both performance management and stakeholder 
management as the well-defined benefits have to be communicated to stakeholders at the 
outset to ensure that the  stakeholders are committed to benefits (Sapountzis, 2013; Mossalam 
and Arafa, 2016).  
 
Mossalam and Arafa (2016) proposed that moving forward BRM processes should be merged 
into most of project, programme or portfolio management processes. It is important to be 
mindful of the planned benefits throughout the lifecycle of a project that is straight from 
initiation and past the closeout. It is also important to cater for benefits management once the 
project has been closed out to allow for benefits transition and sustainability. 
 
2.6 Benefits management in clinical trials 
 
Benefits management in clinical trials is driven by There is  a principle  in clinical research known 
as beneficence.  Beneficence campaigns for maximizing possible benefits and minimizing possible 
harms as demonstrated in figure 12 (Emanuel, 2000; Rid et al., 2010; Grankvist and Kimmelman, 





Figure 12 Risk-benefit assessment and justification. 
 
2.6.1 Risk-benefit assessment of a clinical trial  
 
IRB determine whether the balance between the risks and benefits of a proposed study is 
reasonable or proportional (Musschenga et al., 2007). Useful clinical research has to address a 
health problem, build on existing knowledge and prioritize the patient (Ioannidis, 2016). The 
clinical trial must show value for money while being transparent (Ioannidis, 2016). IRB compare 
risks and benefits, but do not weigh them against each other as IRB generally lack conceptual 
frameworks for identifying and assessing risks and benefits (Musschenga et al., 2007).  Benefit 
assessment in clinical research is not well conceptualized and is often ad hoc, rather than 
standardized and systematic (Churchill et al., 2003; Barke, 2009). 
 
There are limitations and challenges in describing scientific benefits with greater specificity can 
and the lack of specificity can have adverse consequences (Emanuel, 2000; King, 2000; Churchill 
et al., 2003). The vagueness in the description of benefits contributes to therapeutic 
misconception in subjects and leads to overestimation of the likelihood of benefits (Churchill et 
al., 2003). Candilis et al. (2006) has questioned the overall decision-making process of the IRB as 
the lack of a set criteria is a clear limitation. As a guide for IRB decision making, the Belmont 
Report and Common Rule only requires that participants should be provided with a description 
of any benefits that may be “reasonably” expected from the research (Musschenga et al., 2007). 
Even if the risks are minimal, some clinical research might have non-generalizable results that are 
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unlikely to be disseminated or in which the intervention could never be practically implemented 
even if effective (Barke, 2009). This means that risk-benefit decisions are made without a clear 
criteria and in the face of uncertainty with regard to patient benefits and study rationale 




Aside from the beneficence obligation, clinical research is also surrounded by uncertainty. Early 
phase trials represent the point of maximum uncertainty about both the safety and utility of new 
interventions (Barke, 2009; Grankvist and Kimmelman, 2016; Habets et al., 2017). Only 8–10% of 
the interventions entering early stage studies lead to market authorization and less than 8% of 
these approved drugs offer an increased therapeutic benefit over existing drugs (Light et al., 
2013; Hay et al., 2014; Habets et al., 2017).  
 
2.6.3 Quality Assurance 
 
There are also quality concerns about the high throughput of publications of findings from clinical 
trials (Borgerson, 2016). A study that analysed 400 clinical studies in the United States revealed 
that 30% had not shared results through publication or through results reporting in 
ClinicalTrials.gov within 4 years of completion (Saito and Gill, 2014). There is also evidence of a 
lack of consistency in following trial protocols and selective reporting by researchers (Al-Marzouki 
et al., 2008). Researchers elect only to reveal favourable outcome of trials which brings up a 
question of reliability in the reports (Al-Marzouki et al., 2008). With the high quantity and low 
quality, practitioners battle to consume it all and most of it ends up being of no benefit to the 
patients (Borgerson, 2016). 
 
2.7 This Study  
 
The benefits of scientific research are complex and difficult to predict (Barke, 2009). It is because 
of this complexity and the uncertainty with clinical trials as well as the need to ensure clinical 
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utility, that Ioannidis (2016) argued that reform and improvement to performing clinical research 
are overdue. Continuous improvement approach is a philosophy of on-going improvement which 
involves everyone in the organization on a day to day basis in a constant quest for continuous 
incremental improvement on all fronts (Thorp, 1999; Sapountzis, 2013). The philosophy simply 
starts with documented processes for simplicity and improvement. Once the improvements have 
been made, the improvements are standardized and integrated into the organization’s 
processes. Moving forward, the performance of the new processes are monitored and the whole 
processes repeated (Jha et al., 1996; Sapountzis, 2013). There is an element of “Plan-Do-Check-
Act” cycle for continuous improvement (Sapountzis, 2013).  
 
The willingness to constantly improve and better the organizational approach and processes  and 
using lessons learnt from project to project, would be a way to address achieving the intended 
purpose of clinical projects (Thorp, 1999; Sapountzis, 2013). There seems to be a need and room 
for application of BRM processes in clinical research to ensure that all the benefits are realized 
and maximum value is derived. There is evidence that the use of BM practices enhances the 
likelihood of projects achieving organisational goals (Ward and Daniel, 2006; Serra and Kunc, 
2015). With proper application of management principles and BRM, a clinical trial should be 
completed on time and on budget and should serve its intended purpose. Guidelines on how to 
manage clinical trials are useful and key to the success of clinical trials, however, there is a gap 
and room for continuous improvement on how to manage and evaluate the intended purpose of 
the clinical trial (benefits).  
 
This work is intended to add to the existing clinical trials management knowledge by proposing 
the idea of incorporating existing guidelines/processes used currently to manage clinical trials 
and BRM processes that have been used to manage benefits of projects in other industries.  This 
is with the assumption that there is a need for these processes and that there is a benefits 
management limitation in the existing processes. Benefits management needs to be integrated 
into existing project management practices rather than simply “bolted on” (Ward et al., 1996; 
Sapountzis, 2013). An integrated management model that merged existing project management 
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and benefits management processes has been shown to work (Mihić et al., 2012; Mossalam and 
Arafa, 2016). In Serbia, the projects management processes of energy efficiency in public 
buildings was integrated with those of benefits management and this improved the achievement 
of maximum benefits for the community (Mihić et al., 2012). The intergraded model achieved 
benefits such as energy savings, greenhouse gas reduction, comfort improvement, etc. (Mihić et 

























3 Research Methodology 
 
3.1 Research Purpose  
 
There is an ongoing need for effective diseases interventions. The path to obtaining an 
intervention that has been certified safe and effective, is that of uncertainty and risks to the 
human participants of clinical trials. This work aimed to explore the management practices and 
processes that are used to increase the chances of the intended benefits of a clinical trial, being 
realized. This was done using a systematic inquiry of the defined research problem using  
appropriate methods to gather adequate and representative evidence (Amaratunga et al., 2002).   
 
3.2 Research Philosophy  
 
Understanding the assumptions about knowledge and reality that underpin research was useful 
in designing and interpreting this research (Bunniss and Kelly, 2010). There are several distinct 
philosophical approaches to developing research (Amaratunga and Baldry, 2001). Paradigms are 
sets of beliefs and practices, shared by communities of researchers, which regulate inquiry within 
disciplines (Bunniss and Kelly, 2010). The various paradigms are characterised by differences in 
their ontological (nature of reality), epistemological (nature of knowledge) and methodological 
(nature of approach to research) approaches to conceptualising and conducting research 
(Bunniss and Kelly, 2010). There are several major paradigms positivism, post-positivism, 
interpretivism and critical theory shown greater detail in table 7 in Appendix A (Bunniss and Kelly, 
2010). For this study, positivism and interpretivism were considered as they are two commonly 




Positivism searches for causal explanations and fundamental laws, and generally reduces the 
whole into its simplest possible elements in order to facilitate analysis (Amaratunga and Baldry, 
2001). The positivism approach focuses on facts and considers the world to be independent of 
and unaffected by the researcher (Amaratunga and Baldry, 2001; Bunniss and Kelly, 2010; Ritchie 
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et al., 2013). There is a need to formulate hypotheses and test them (Amaratunga and Baldry, 
2001). Positivism relies on numbers and the skills of the researcher as a mathematical or 
statistical analyst (Ritchie et al., 2013). The subject under analysis should be measured through 
objective methods rather than being inferred subjectively and through sensation, reflection or 
intuition (Amaratunga and Baldry, 2001).  
 
3.2.2  Interpretivism 
 
The basic belief is that the researcher and the social world impact on each other (Ritchie et al., 
2013). Facts and values are not distinct which means findings are inevitably influenced by the 
researcher's perspective and values, thus making it impossible to conduct objective, value free 
research, although the researcher can declare and be transparent about his or her assumptions 
(Amaratunga and Baldry, 2001; Bunniss and Kelly, 2010; Ritchie et al., 2013). The interpretative 
approach understands reality as holistic and socially constructed rather than objectively 
determined (Amaratunga and Baldry, 2001). The interpretative approach tries to understand 
meanings and explain a phenomenon, rather than search for external cause or fundamental laws 
(Amaratunga and Baldry, 2001). Ideas are developed through induction from data (Amaratunga 
and Baldry, 2001; Bunniss and Kelly, 2010). 
 
3.3 Research Approach  
 
The interpretivism approach was adopted for this study to evaluate the current use and 
application of BRM processes in clinical trials. The positivism approach was not applicable in 
exploring the existence on BRM processes in clinical trials as the exploration was based on 
subjective views and opinions of management. The positivism approach involves making 
predictions or using scientific experiments to describe or measure a phenomenon and this was 
not a possibility for this study. It was therefore decided that to accurately address the research 




3.3.1 Quantitative or qualitative data 
 
The research approach used would yield qualitative findings due to the inductive nature of the 
study to describe BRM processes and evaluate the effectiveness of those processes. Qualitative 
research, broadly defined, means any kind of research that produces findings not arrived at by 
means of statistical procedures or other means of quantification (Golafshani, 2003). Qualitative 
research is best characterized as a family of approaches whose goal is understanding the lived 
experience of persons who share time, space and culture (Frankel and Devers, 2000a). The logic 
of qualitative research is often inductive, rather than deductive, and consists of describing 
people's and groups' particular situations, meanings and experiences (Frankel and Devers, 
2000b).  
 
In contrast, quantitative research employs deductive logic, often drawing heavily on existing 
theoretical and substantive prior knowledge to conceptualize specific situations, and to predict 
what will happen to particular people or groups, and why (Frankel and Devers, 2000b). 
Quantitative research could not be used in this study as it would require experimental methods, 
testing of hypothetical generalizations using some unit of measurement and analysing causal 
relationships between variables (Golafshani, 2003). Quantitative research emphasises facts and 
causes of behaviour and the information is in the form of numbers that can be quantified and 
summarized (Golafshani, 2003). The mathematical process is the norm for analysing the numeric 
data and the final result is expressed in statistical terminologies (Golafshani, 2003).  
 
The qualitative research process is emergent, non-linear and non-sequential as data collection 
and analysis often proceed simultaneously (Frankel and Devers, 2000b). In light of early findings, 
subsequent data collection and analysis procedures may be modified to gather more specific 
information, or explore new and unanticipated areas of interest (Frankel and Devers, 2000b). The 
researcher and research subjects, their relationship, and the research setting are all subject to 
development and change (Frankel and Devers, 2000b). Commonly used qualitative research tools 
include the field work approach, interviews and surveys, audio-visual records, and the study of 
documents (Frankel and Devers, 2000a).  Qualitative research approaches are only as good as 
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the questions they set out to illuminate (Frankel and Devers, 2000a).  Good qualitative studies 
answer clearly stated, important research questions and how these questions are formulated has 
implications for conducting the research (Frankel and Devers, 2000b). 
 
3.4 Sampling Strategy  
 
Sampling is used because studying whole populations can be expensive and/or not feasible 
(Bhattacherjee, 2012). Sampling is therefore used to study a subset of a population of interest 
for purposes of making observations and statistical inferences about that population 
(Bhattacherjee, 2012). This study used purposive sampling strategy rather than random sampling 
strategies. Purposive sampling strategies are designed to enhance understandings of selected 
individuals or experiences of groups by selecting "information rich" cases, that is individuals, 
groups, organizations, or behaviours that provide the greatest insight into the research question 
(Devers and Frankel, 2000). Another advantage of purposive strategies is that  the strategy can 
be revised throughout the research process as more knowledge of the setting and subjects are 
obtained (Devers and Frankel, 2000).  
 
HIV clinical trials were used to explore a multi-perspectival understanding of the application of 
BRM processes in clinical trials and evaluate the perception of their efficiency. It is important to 
include cases in a study that offer an opportunity for learning (Tellis, 1997; Bhattacherjee, 2012). 
This lead to the choice of multiple clinical trials under one area, HIV research, to strengthen the 
results by replicating the pattern matching, thus increasing confidence in the robustness of the 
theory (Amaratunga and Baldry, 2001). This strategy was intended to set the investigation of BRM 
processes operating in a real-life context and to collect multiple perspectives from people with 
different viewpoints on what is being observed to build up detailed and in-depth understanding. 
 
A pilot questionnaire was used for the first few accessible participants to check and/or verify the 
quality of the questions. The questionnaire was then adjusted accordingly for subsequent 
correspondents to improve the comprehensiveness of the data collection. There was flexibility 
incorporated into the approach specifically when choosing people to contact and include in the 
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study. This was shaped by the ongoing findings, the ease of access to individuals and 
recommendations from those that had already participated in the study. This approach was 
similar to case study research in that it included some deduction based on prior theory as shown 
in figure 13 (Perry, 1998). Prior theory and theory emerging from the data are always part of any 




Figure 13 Inductive and deductive approaches to case study research (Source: Perry (1998)) 
 
The first case on the left hand side of the figure is almost pure grounded theory (Perry, 1998). 
But data collection and analysis of the next cases on the left-hand side is informed by preliminary 
concepts from the first case and from prior theory (Perry, 1998). This prior theory then informs 
the interview protocol used for data collection in all the main cases, as shown on the right-hand 
side (Perry, 1998).   
 
It is important to highlight that the probability of the selection in this study cannot be accurately 
determined as the sample selection was based on a non-random criteria of expert sampling of 
clinical trials management and convenience (Bhattacherjee, 2012). The sampling frame used may 
therefore not be entirely representative of the population at large and inferences from this study 





3.5 Research Instrument 
 
The study was in two parts with the first part being a critical review of documented BRM 
processes in several general clinical trial guidelines referenced by HIV publications. The second 
part of the study considered different perspectives of the actors involved in management of 
clinical trials.  The advantages and disadvantages of each method is shown in table 3.  
 









• Relatively easy to 
obtain  
• Maybe compared 
against selected 
criteria  
• Unobtrusive  
• Can be bulky, difficult 
to transport and code  
• Issues of accuracy and 
completeness difficult 
to assess   
• Social context of 
document production 
difficult to reconstruct 
Surveys  Attitudes 
and beliefs 
• Can be administered 
to a large number of 
subjects  
• Relatively 
inexpensive way of 
sampling opinions, 
attitudes and values 
• Results are easily 
quantified  
• Generalizable  
• Limited or fixed choice 
questions may give 
results that are not 
factual 
• Little control over 
context of responses 
• Difficult to assess 
overall accuracy of 
responses  
• Potential for 
oversimplifying issues    
 
3.5.1 Part 1: Critical review of clinical trials guidelines  
 
This section of the study will take format of a literature review of the guidelines documents that 
were used in HIV clinical trials. The documents will be systematic searched for any mention of 
BRM processes and/or proposed approaches to maximizing clinical research benefits. The 
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following protocols and ethical guidelines as well as other publication linked with HIV clinical 
trials were reviewed for the mention of BRM processes and/or context:   
• The Nuremberg Code, 1947 
• Declaration of Helsinki, 1964 (last updated in October 2000) 
• The Belmont Report, 1979 
• The CIOMS Guidelines, 1982 (last updated in 2002) 
• Ethical Considerations in HIV Preventive Vaccine Research: UNAIDS Guidance Document, 2000 
• Good Participatory Practice: Guidelines for Biomedical HIV Prevention Trials, revised: UNAIDS 
Guidance Document, 2011 
 
 
Figure 14 Reviewing Guidelines. 
The keywords search included: benefits, benefits management, benefits processes, benefits 
assessment, value, effectiveness and purpose. The results were categorized into areas of BRM 
focus such as strategy, benefit identification and benefit planning, benefit realization, benefit 
review and benefit measure. The relevant matches that resulted from the searches were 




•(benefits, Benefits management/processes, 
value, effectiveness, purpose, promise, 
accountable)
Catergorize 
•1) Strategy 2) Identify and Plan 3) Realize 4) 
Review (Measure) and 5) Accountability.
Analyze 
•Patterns, presence, absence, partial 
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3.5.2 Part 2: Survey   
 
The second section of the study was an exploratory cross-sectional assessment of currently 
applied BRM processes as perceived by people actively involved in the management of past or 
ongoing HIV clinical trials. Survey research method involves the use of standardized 
questionnaires to collect data about people and their preferences, thoughts, and behaviours in a 
systematic manner (Bhattacherjee, 2012).  
 
The survey research was used because its inherent strengths compared to other research 
methods.  As stated by Bhattacherjee (2012), these include: 
1. Excellent for measuring a wide variety of unobservable data, such as people’s preferences, 
traits, attitudes, beliefs, behaviours or factual information.  
2. Remotely collecting data about a population that is too large to observe directly.  
3. Questionnaire surveys are preferred by some respondents due to their unobtrusive nature 
and the ability to respond at one’s convenience. 
4. Survey research is economical in terms of researcher time, effort and cost than most other 
methods such as experimental research and case research.  
The questions used in survey research may be unstructured or structured (Amaratunga and 
Baldry, 2001). The unstructured questions ask respondents to provide a response in their own 
words, while structured questions ask respondents to select an answer from a given set of 
choices (Amaratunga and Baldry, 2001). The responses of the subjects to individual questions on 
a structured questionnaire may be aggregated into a composite scale or index for statistical 
analysis. (Amaratunga and Baldry, 2001). 
 
Questionnaires were used establish the knowledge of the managers of any BRM processes for 
ensuring benefits realization and whether those processes, if any, were being used in practice in 
HIV clinical trials. The first contact was with easily accessible participants within the field through 
emails with link to the online survey. This served as a pilot questionnaire to check and/or verify 
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the quality of the questions. The questionnaire was then adjusted accordingly for subsequent 
correspondents. The pre-set categorized questions were sent as they appear in appendix B. 
 
3.6 Data Analysis Technique  
 
This was a qualitative study and the collected data were recorded in coded manner that enables 
analysis with programs such as SPSS for Windows. The data portrayed the current practices of 
BRM in clinical trials and reveal how advanced they are. Data analysis consisted of examining, 
categorizing and/or tabulating the evidence to address the initial propositions of a study (Tellis, 
1997; Bhattacherjee, 2012) .  
 
3.7 Research Instrument validation 
 
Reliability and validity demonstrate trustworthiness, rigor and quality of qualitative research 
(Golafshani, 2003). Triangulation is used to achieve validity and reliability of research affected by 
the perspectives of the researcher and to eliminate bias about some social phenomenon 
(Golafshani, 2003). Triangulation is a validity procedure where researchers search for 
convergence among multiple and different sources of information to form themes or categories 
in a study (Golafshani, 2003). It was for triangulation purposes that this study was in two parts 
with the first part being a critical review of documented BRM processes in several general clinical 
trial guidelines referenced by HIV research publications and the second part of the study 
considered different perspectives of the actors involved in management of clinical trials.   
 
Surveys have been shown to generally have low response rates and this bring up reservations 
about their validity and bias (Radhakrishna and Doamekpor, 2008; Fan and Yan, 2010). To avoid 
most of the factors that lead to low response rates, specifics attempts to better the survey 
development as proposed by Fan and Yan (2010), were implemented. These attempts included 
running pilots surveys, having multiple draft versions to remove deterring elements such as 




3.8 Develop the conclusions, recommendations and implications 
 
Logical reasoning was employed in drawing conclusions on the basis of the evidence without any 
bias. Attempts to demonstrate the validity or reasonableness of the conclusions we also 
undertaken. Any existing processes were compared with theoretical and published BRM 
processes commonly applied in IS/IT projects to establish the degree to which BRM processes are 
present in clinical trial research. This study will enable the assessment of the as-is benefits 
management situation in clinical trials.  
 
3.9 Potential limitation of the approach: 
 
The main reason this approach was taken was due to a limitation in the amount of time available 
to fully explore this phenomenon. Retrieving documents can be difficult and extracting useful 
data from said documents can be subjective and open to interpretation. It is possible that access 
and usage of information from these may be blocked by gatekeepers in this field (Devers and 
Frankel, 2000). There is always that possibility that the questions could have been better phrased 
opening the process up to misinterpretation. There could also be response bias from the 
participants. 
 
Survey research has disadvantages as it is subject to a large number of biases (Bhattacherjee, 
2012). There is the non-response bias which occurs when a small group responds and is not fully 
representative (Bhattacherjee, 2012). There is sampling bias that results due to the method of 
the survey, whereby there is a chance a group of people that do not have access to a platform 
used and are left out (Bhattacherjee, 2012). Social desirability bias is a result of participants may 
offer altered responses to safe face. Other potential biases include the recall bias where the 
participants maybe responding to questions in which they do not remember most of the relevant 
details and the common bias which is when the phenomenon under investigation may not be 




Quality of a study in each paradigm should be judged by its own paradigm's terms (Golafshani, 
2003). While the terms reliability and validity are essential criterion for quality in quantitative 
paradigms, in qualitative paradigms the terms credibility, neutrality or confirmability, consistency 
or dependability and applicability or transferability are to be the essential criteria for quality 
(Golafshani, 2003). 
 
3.10 Research Ethics  
 
Ethics is the moral distinction between right and wrong and what is unethical may not necessarily 
be illegal (Bhattacherjee, 2012). It is difficult to predict ethical predicaments that may arise from 
a research study but it is important to still to be aware of most of the ethical consideration and 
to take necessary steps to address them (Orb et al., 2001; Bell and Wray-Bliss, 2009; Houghton 
et al., 2010). Here are some of the ethical considerations that were considered throughout this 
study: 
 
Disclosure: The participants were fully informed about the nature of the research through an 
explanatory covering email and/or an explanation before the questions (Orb et al., 2001). The 
researcher, along with his supervisor’s contact details will be provided and the participants can 
contact the researcher should they have any questions and or queries regarding study. 
 
Non-maleficence: The people that were approached were made aware that they would not be 
harmed as a result of their participation or non-participation in the study (Bhattacherjee, 2012). 
The risk of participating in this research, never outweighed the importance of the problem being 
studied. 
 
Voluntary participation: The participants were aware that their participation in the study was 
voluntarily and that they had the freedom to withdraw from the study at any time without any 
unfavourable consequences (Bhattacherjee, 2012). The participants were also made aware of the 




Informed consent: All participants were issued and signed informed consent forms that clearly 
described their right to not participate and a right to withdraw before their responses in the study 
are reported (Houghton et al., 2010). 
 
Confidentiality: The identity of the participants was not divulged in the report to protect their 
interests and future well-being (Bhattacherjee, 2012). No personal or sensitive details of the 
participants were collected.  
 
Analysis and reporting: All findings were reported without influence of the researcher and 
participant relationship or the researcher’s subjective interpretations of data or the impact on 
the intended research (Orb et al., 2001; Houghton et al., 2010).  
 
Conflicts of interest: There were no potential conflicts of interest to declare. 
 
The research protocol was provided to the University of Cape Town Ethics Committee for review 
and approval, with study commencing once approval was granted. All data and information 
collection during this study was kept strictly confidential, with the researcher maintaining sole 
access to the data. 
  
3.11 Research Methodology Summary  
 
Table 4 Summary of the research methodology  
Research Philosophy Interpretive  
Research Approach Qualitative  
Data Collection Method Literature and policy Review  
Survey Questionnaires  







This chapter presents the findings from both parts of this study. The first part was the critical 
review of documented BRM processes in several general clinical trial guidelines referenced by 
HIV publications. The second part of the study considered different perspectives of the actors 




The official documents that were reviewed were either clinical trial protocols, standard operating 
procedures, policies, guidelines and publications that appear in table 6. All the respondents of 
the survey were at different levels of management for the different HIV clinical trials and had 
diverse professional backgrounds as shown in table 5.  
 
Table 5 showing the occupations of the people that responded to the survey  














14 of the 19 respondents in this study claimed to have been involved at the planning phases of 











In order to identify BRM processes used to manage HIV clinical trials benefits, keyword searches 
of publicly available HIV clinical trials documents were conducted. Aspects of benefits 
managements that were found in these documents are detailed in table 6 and were grouped into 
aspects that belong under benefits management plan, benefits identification, benefits planning, 
benefits measuring, benefits realization, benefits review, benefits review and benefits report. 
 
In the multiple documents and guidelines that were reviewed, there were no clearly detailed, 
separate and documented benefits management processes in HIV clinical trials. There are 
however, processes that were arguably elements of BRM that are alternatively termed and 
incorporated within other managements processes but appear to be aimed at managing benefits. 
These are processes in the general management and approach to clinical trials that include 
aspects that bear similarity to processes in IT/IS benefits management.  




Table 6 Different sections that are benefits related or relevant that have been extracted from multiple documents and guidelines 
used in HIV clinical trials 
  WHO Handbook for good 
clinical research practice 



































 Beneficence  
 




 X  X X The federal regulations 
do not define “direct 
benefits” nor explain how 
they differ from indirect 
benefits or other types of 
benefit (Ross, 2006). 
 X  The 
assessment 


















Principle 3: Before research 
involving humans is 
initiated, foreseeable 
risks and discomforts and 
any anticipated benefit(s) 
for the individual 
research subject and 
society should be identified.  
 X  X X Risks to subjects are 
reasonable in relation to 
the anticipated benefits. 
 
(CFR) 45 part 46: it is 
necessary to determine 
whether the research 
offers the prospect of 
direct benefit as long the 
risk is justified by the 
anticipated benefit to the 
subjects (Ross, 2006). 











  WHO Handbook for good 
clinical research practice 


































Principle 4: Research 
involving humans should be 
initiated only if the 
anticipated benefit(s) for 
the individual research 
subject and society 
clearly outweigh the risks. 
Although the benefit of the 
results of the 
trial to science and society 
should be taken into 
account, the most 
important considerations 
are those related to the 
rights, safety, and 
well-being of the research 
subjects. 
 
 X Institutional 
Review Boards 
(IRBs) should 
weigh the risks 
of medical 
research against 
its benefits, and 
to assess the 
ratio between 
them  
X    X  X X 
Benefits 
measuring 
A favourable risk/benefit 
assessment.  
  X X Only those within the 
research, Not outside or 
later  
 X X X 
Benefits 
realization  
X   X X  X  X X X 
Benefits Review  X   X X  X  X X X 
Benefits report  X   X X  X  X X X 




4.2.2 The online survey  
 
4.2.2.1 The	survey	metrics	
The survey response rate is defined as the number of completed units divided by the number of 
eligible units in the sample (Fan and Yan, 2010). In this study over 2000 emails with the link to 
the survey were sent out. The e-mail addresses were obtained from websites and directories of 
the several research groups and networks that work with HIV clinical trials. A copy and paste 
approach was used and this made it difficult to keep track of the exact number of emails sent 
out. This was further complicated by failed-to-sent email addresses that were either deactivated 
or rejected the survey e-mail as spam. The exact response rate number of this study is therefore 
unknown but with only 19 responses from the numerous emails that were sent out, the response 
rate was assumed to be low.   
 
4.2.2.2 Familiarity	with	BRM	and	BRM	processes		
Only 1 individual out of the 19 respondents was aware of BRM and had actually applied BRM 
processes to manage clinical trials. When asked about their familiarity with BRM, 74% of the 
respondents stated that they had never heard of BRM and BRM processes as shown on figure 16. 
The remaining 20 percent admitted to not using BRM processes even though they were familiar 
with them. 
 




When asked about the existence of comprehensive processes used to manage benefits of clinical 
trials, 74% of the respondents believed that BRM processes existed in HIV clinical trials even 
though they were not familiar with BRM processes as shown in figure 17. These were some of 
the comments from the participants when asked about the existence of BRM processes in HIV 
clinical trials: 
“I am not aware of any but that doesn't mean they don't exist.” 
and 










There are detailed guides on important processes to include in clinical trials management but 
there is limited information on benefits management processes. Most of the methods are more 
about standardising the day to day management approaches or output focused. There were 
however, processes specific to clinical trials that also appear be used for managing benefits in 
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clinical trials or show similarity to IT/IS BRM processes. The list below sums up what is listed on 
table 6 and what each document includes. 
• WHO Handbook for good clinical research practice (GCP): guidance for implementation: There 
are aspects of this document that speak to benefits planning and identification.  
• ICH Harmonized Tripartite Guideline: Guideline for good clinical practice: no aspects of benefits 
management were identified.  
• World Medical Association Declaration of Helsinki: Only highlighted identifying more benefits 
than risks. 
• Food and Drug Administration (FDA): There are aspects of the FDA documents that touch on 
benefits planning, identification and measuring.  
• Consolidated Standards of Reporting Trials CONSORT and Pragmatic Explanatory Continuum 
Indicator Summary 2 (PRECIS-2) Tool: These two documents only mention how to report clinical 
trials but there was no mention of benefits in both of the documents. 
• The Belmont Report: Touches on aspects of benefits assessment.  
• The Nuremberg Code: Only advocates that clinical trials should yield fruitful results. 
During the review of the clinical trial processes, there were terms and processes that were unique 
to clinical trials but appear to be aimed at managing the clinical trial promise. These were: 
Beneficence: Beneficence refers to the ethical obligation to maximize benefit and to minimize 
harm (WHO, 2005).  This principle gives rise to norms requiring that the risks of research be 
reasonable in the light of the expected benefits and that the research design be sound (WHO, 
2005). The principle of beneficence bears a close relationship to the GCP requirement that 
research should be justified on the basis of a favourable risk/benefit assessment  as stated in the 
Belmont Report shown in table 6 (WHO, 2005). 
 
Endpoint: An endpoint is the clinical or surrogate item that is being assessed to determine 
whether the drug or intervention is effective (Bairu and Chin, 2012). Early in the development 
and evaluation of an intervention, regulatory agencies use endpoints to determine the safety and 
biological activity of an intervention and later on, endpoints help investigators to decide whether 
a drug provides a clinical benefit (Bairu and Chin, 2012). A good clinical endpoint should be 
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clinically relevant, reflect the overall disease being treated, informative, sensitive, discriminating, 
reliable and robust (Bairu and Chin, 2012).  
 
Interim analysis: Interim analysis is a process of examining and analysing data as it accumulates 
during a clinical trial, either formally or informally, during the conduct of the clinical trial (Chow 
and Liu, 2008). Interim analysis seeks out errors, safeguards the blinding of a study and assesses 




When analysing the responses to the survey, it was important to keep in mind that 74% of the 
respondents admitted to lack of familiarity with BRM and this was a possible limiting factor in 
providing specifics HIV clinical trial BRM and BRM processes.  Other questions were included in 
the survey to still put piece together how HIV clinical trials management deals benefits even if 
they are unfamiliar with formal BRM and BRM processes.   
 
4.3.2.1 Do	clinical	trials	achieve	what	they	set	out	to?	
There was an overall confidence from the respondents that clinical trials delivered on their 
intended purpose with only 3 respondents out of the 19 giving a percentage estimate below 50% 
as shown in figure 18.  
 





Figure 19 The interpretation of the focus of the general management approach to managing 
HIV clinical trials by the respondents. 
 
4.3.2.2 Management	Approach	
Figure 19 shows that 84% of the respondents stated that the overall management approach in 
HIV clinical trials is focused on both outputs and outcomes. The other 16% of the respondents 
believed that the general management approach was focused only on outputs.  
 
4.3.2.3 Accountability	for	realizing	benefits	and	sustaining	them?	
The principal investigator was identified as the stakeholder in clinical trials that is responsible for 
the realization and sustaining benefits by 53% of the respondents as shown in figure 20.  Other 
respondents mentioned either the project manager, the data monitoring committee or IRB as 





Figure 20 The stakeholder charged with championing and sustaining benefits 
 
Some of the detailed responses to the question of who was accountable for realizing and 
sustaining clinical trial benefits, are listed below. 
“They are spread out and performed by different people.” 
 
“All of the above and the team.” 
 
“It is multiple stakeholders and teams from project managers to principal investigators.” 
 





Figure 21 Establishing whether there is a set timescale to realizing HIV clinical trials benefits 
 
4.3.2.4 Benefits	timescale?	
When assessing whether a time frame was placed on the realization of HIV Clinical trials benefits, 
47% of the respondents claimed that there was a set time for benefits realization as shown in 
figure 21. Those that said there no set time were 32% of the respondents with the remaining 21% 
claiming to either not know enough or that there are other variables to factor in. these were 
some of the comments from the respondents:   
“The timescale is based on the endpoint results and the decision by the data monitoring 
board.” 
 
“I don't know.” 
 
“Benefits are realized through peer reviewed publication and meritorious publications and 








4.4.1 Literature  
 
Table 6 was designed with reference to what is known in published work about benefits 
management processes. Similar processes or aspects of clinical trials guidelines that appeared to 
match those in BRM literature, were populated in table 6. Several of the reviewed guidelines 
appeared to aspects that fit into benefits management plan, benefits identification, benefits 
planning and benefits measuring. The review showed that the guidelines lacked aspects of actual 
benefits realization, benefits review and benefits reporting or follow-up.  
  
4.4.2 The perception of current practices by the respondents 
 
The majority of respondents claimed that the processes used to manage benefits of HIV clinical 
trials are below where they need to be as should in figure 22. There was 26% of the 
respondents who felt that the processes used to manage benefits of clinical trials were on the 
same level as other industries. An equal 26% of the respondents excused themselves from 
commenting due to their lack of knowledge of BRM. 
 
 
Figure 22 The respondents ranked the benefits management processes currently used in 





Figure 23 The respondents were asked whether they felt there was a need to improve the 
processes currently used to manage benefits of HIV clinical trials. 
 
Of the 19 respondents, 11 of them were open to improvements being added to the current ways 
of managing HIV clinical trials benefits as shown on figure 23. Below are some of the additional 
comments by the respondents with regards to the need for improvement of processes in HIV 
clinical trials.  
 
“Overall, preventive HIV vaccine trials offer few benefits to the individual participant. The 
benefits are largely for the scientific field, which stands to learn from the trial. Until we actually 
have a licensed vaccine that can be deployed, the benefits will continue to be limited.” 
 
“We do need to improve our processes.” 
 





This chapter discusses the finding of this study that were presented in chapter 4. This chapter 




It is important that there is contextualized and cautious interpretation and generalization of the 
research findings of this study. The findings from the review of the guidelines and literature can 
be generalized as these documents are applicable in most clinical trials not just HIV clinical trials. 
There should be limited  generalization of findings from survey part of this research as there were 
concerns because of the low response rate obtained (Radhakrishna and Doamekpor, 2008). This 
is to avoid reaching conclusions using findings that are vulnerable to both sample error and 
sample bias due to the low response rate (Nulty, 2008).  
 
The low response rates may have been due to the structure of the questionnaire. Even before 
respondents decide whether they will participate in the survey or not, the response rate is 
significantly influenced by factors such as subject, formatting and length of the survey (Nulty, 
2008; Fan and Yan, 2010). Numerous attempts were made as proposed by Fan and Yan (2010)  
and to the best abilities of the researcher, to improve the quality and structure of the survey in 
order to develop a survey with a satisfactory response rate. There is lack of consensus in the   
literature about an exact number that is considered a satisfactory response rate because little is 
known about whether non-respondents differ from respondents (Radhakrishna and Doamekpor, 
2008; Fan and Yan, 2010). Had the response been 100%, the question of generalizing the findings 
does not arise because everyone responded (Radhakrishna and Doamekpor, 2008). As soon as 
the response is not 100% and is low, the questions of why some stakeholders did not respond 
comes up and whether the data are only valid for those that responded (Radhakrishna and 
Doamekpor, 2008). The survey results obtained from this small sample are not likely to be an 






What is apparent and central to the management approach and documentation of clinical trials 
is the heavy focus on ethics and the safety of all the human participants. This is mostly based on 
hard historical lessons. The Nuremberg Code, for example, was formulated in 1947, in 
Nuremberg, Germany, by American judges sitting in judgment of Nazi doctors accused of 
conducting murderous and torturous human experiments in the concentration camps (Shuster, 
1997). Informed consent was the core of the Nuremberg Code but it served as a blueprint for 
today's principles that ensure the rights of subjects in medical research camps (Shuster, 1997).  
The Declaration of Helsinki serves as a guide on the obligations of physician-investigators to 
research subjects and focuses on the protection of subject rights and to those involved in medical 
research that involves humans  (Shuster, 1997; Otte et al., 2005). It is for these reasons that 
designing, conducting, recording and reporting trials that involve the participation of human 
subjects is mostly focused on protecting the rights, safety, and well-being of trial subjects (Otte 
et al., 2005).   
 
The GCP only controls scientific experimentation and leaves unaddressed most management 
issues (Bongiovanni et al., 2015). Complexity in management is a result of sizeable projects that 
have a high degree of uncertainty, have numerous interacting elements and apply new methods 
(Vidal and Marle, 2008). Clinical trials involve recruiting large patient sample sizes, managing 
multisite teams, inclusion or exclusion criteria, scheduling, collaborations and unpredictability 
clinical outcomes and all these give rise to complexity (Bossert et al., 2002). The focus of a project 
plan and management should be placed on the connection between project goals and the 
purpose behind those goals (Hubbard, 2000). Due to the uncertainty of clinical trials, it is hard to 
make any guarantees on benefits even when the trial is efficiently managed as the trial may still 
not produce the desired outputs and not fulfil the purpose (Farrell, 1998; King, 2000; Farrell et 
al., 2010). In other words, the “efficacy” of an experimental intervention (i.e. a measure of the 
success of an intervention in an artificial setting) may not translate into its “effectiveness” (i.e. a 




Too much focus on delivering the classic project iron triangle performance measures (cost, time 
and scope) creates an “output-focused” mentality which limits the effectiveness of the 
organisation to realise benefits from its projects (Chih and Zwikael, 2015). The respondents 
believe that the management approach to HIV clinical trials is focused on both outputs and 
outcomes. Which means management seeks to put in place processes that are orientated on 
deliverables, efficiency as well as benefits and value. The management approach to clinical trials, 
according to the survey, is therefore focused on running and managing clinical trials as efficiently 
as possible at the same time getting as much value out of clinical trials as possible. This 
management style implies that that there is a possibility that benefits management processes 
exist in clinical trials or that there is potential for implementation of BRM processes if they 
already do not exist. 
 
BRM is an approach for the optimization or maximization of benefits from organizational change 
programmes (Sapountzis, 2013). To realize benefits, changes have to happen from the top 
through effective governance. The respondent in this study are in a great position to influence 
BRM in clinical trials as the majority of them indicated in figure 15 that they are involved in the 
strategic planning of clinical trials. ul Musawir et al. (2017) acknowledges that interaction 
between project governance and benefit management process is more complex than a simple 
cause-and-effect relationship but project governance creates the roles, responsibilities, and 
accountabilities that enable benefit management. The insertion of changes within organizational 
processes does not automatically result in benefits but benefits arise when the people in the 





Throughout this investigation, several clinical trial documents and guidelines were scrutinized 
but BRM processes in HIV clinical trials. People who work and manage clinical trials were used as 
sources of information in exploring benefits management in clinical trials. The spread of expertise 
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and the involvement in clinical trials by the survey respondents were broad and diverse enough 
to offer confidence in their observations and comments. The respondents were at different levels 
of management, different skillsets, played different roles in clinical trials and worked for different 
HIV trials and appear to have been involved in benefits planning, identification and putting 
together a benefits plan of their perspective clinical trials.  
 
This study looked to unearth BRM processes in clinical trials and establish an understanding of 
how HIV clinical trial benefits were managed and realized. None of the documents that were 
reviewed in this study were solely focused on benefits management. There was several mentions 
of benefits and their importance but not BRM processes. The guidelines highlighted the 
importance of risk-benefit assessment of every clinical trial but did not give specifics on how to 
go about conducting the risk-benefits assessment. Even though there was limited familiarity 
within clinical trial management with BRM and BRM processes, there was high confidence levels 
that clinical trials deliver what they intend to achieve as shown in figure 18. This study was not 
able to explicitly locate BRM processes in clinical trials however, the positive outlook on clinical 
trials achieving their goals by the respondents implied that good management practices were in 
place somewhere. 
 
What was apparent was that benefits and benefits assessment were treated as ethical issues. 
According to the Belmont Report,  the term “benefit” is used in the clinical research context to 
refer to something of positive value related to health or welfare (WHO, 2005). Emanuel (2000) 
pointed out that it is an ethical requirement that potential benefits of a trial must always be 
higher than potential risks posed by the clinical trial. Successful clinical trial findings are those 
that fit the principle of generalizability which dictates that the findings must be applicable to 










It was worth comparing of how clinical trial benefits were managed to how IT/IS and/or general 
BRM literature suggests project benefits should be managed. Below are some of the common 
practices of BRM and what are referred to as BRM pillars.  
 
Strategic fit: Benefits have to align with the organization's overall strategy (Chih and Zwikael, 
2015; Mossalam and Arafa, 2016). Benefits arise when changes are introduced  through effective 
governance and enable organizations do things differently (Peppard et al., 2007; Mossalam and 
Arafa, 2016). Realistic delivery methods for the project under analysis will lead to success given 
the context in which the organization is operating and its constraints (Chih and Zwikael, 2015; 
Serra and Kunc, 2015; Mossalam and Arafa, 2016). As 74% of the respondents were involved in 
the strategic planning of the respective clinical trial, they would be in a position to suggest and 
implement ways to align clinical benefits with the overall strategy.   
Planning: BRM literature states that to deliver the project promise, the first step is for an 
organization to move away from an output focused style of management to a benefit orientated 
style of management (Chih and Zwikael, 2015). An overwhelming 84% of the respondents 
indicated that the style of management in clinical trials was both output and outcomes focused 
as shown in figure 19. It is important for a project to start  with the end in mind by noting its 
expected outputs, outcomes, and benefits in the business case (Serra and Kunc, 2015; Mossalam 
and Arafa, 2016). The benefits must be measurable which would mean that each benefit has to 
have a baseline (Chih and Zwikael, 2015). The benefits planning in clinical trials should be included 
in the trial protocol as the trial is developing. Most of the respondents said that they were 
involved in the planning of their respective clinical trials that worked on which implied that they 
are aware and were influential on the general planning of clinical trials including benefits 
planning. 
 
Benefits identification: To direct the identification of benefits, principle 3 of the W.H.O states that 
before research involving humans is initiated, foreseeable risks and discomforts and any 
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anticipated benefits for the individual research subjects and society should be identified (WHO, 
2005). There are parts of the process however, that require refining such as parameters used to 
identify and classify direct  benefits need further clarification (Koonrungsesomboon et al., 2016). 
Tumor shrinkage or remission, an extension in life expectancy of patients, or an improvement in 
the patients’ quality of life in cancer trials can be considered as direct benefits but there are 
disagreements in the industry  (Koonrungsesomboon et al., 2016). The guidelines documents and 
the respondents all clearly acknowledged the importance of managing clinical trial benefits by 
identifying and assessing them. 
 
Benefits Review: Project outputs and outcomes are frequently reviewed and realigned to the 
current expectations (Serra and Kunc, 2015). For tracking purposes, it is important for each 
benefit to have an owner that is responsible for that benefit (Lin and Pervan, 2003; Chih and 
Zwikael, 2015). In clinical trials, the overall responsibility for delivering the trial lies with the 
principal investigator and this would explain why the principal investigator was selected by the 
majority of respondents. (Goodarzynejad and Babamahmoodi, 2015). Other respondents named 
five other stakeholders as the ones that are supposedly championing BRM besides the principal 
investigator. It might be beneficial of adopt this approach of spreading out the BRM 
accountability per benefit to several people enable following up on benefits and sustaining them.   
Benefits Realization: Although benefits are not the only criteria to evaluate project success, they 
are a measurement of how valuable a project is (Serra and Kunc, 2015). Project outcomes are 
monitored by the organisation after project closure in order to ensure the achievement of all 
benefits expected in the business case (Serra and Kunc, 2015). There is often a lag in benefits 
accumulation after the implementation it which means the outcome monitoring continues until 
each of the expected benefits has either been achieved or it is clear it will not materialize 
(Peppard et al., 2007). Clinical trials can run for years and it is important to maintain and update 
a list of realized and anticipated benefits as way of keeping track of them. The respondents 
believed that benefits are realized when the intervention is licensed or through peer reviewed 
publications. IT/IS literature highlights the importance of a timescale for BRM purposes (Chih and 
Zwikael, 2015). A combined 10 out the 19 respondents said that there was no timescale to 
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benefits management in clinical trial and/or it is no easy to have a timescale. This brings into 
question the efficiency and accuracy of the processes that currently exist in clinical trials 
especially when following up on benefits once the clinical trials has reached completion. 
 
Benefits review: In order to show added value, benefits must be measured in a systematic manner 
(Ashurst et al., 2008). It is therefore important that planned benefits have to be monitored so 
that they are not lost as the project continues (Sapountzis, 2013). It is also worth pursuing 
additional  benefits that may arise as the project progresses (Sapountzis, 2013). Principle 4 of the 
WHO states that research involving humans should be initiated only if the anticipated benefit(s) 
for the individual research subject and society clearly outweigh the risks (WHO, 2005). Principle 
8  of the WHO states that research involving humans should be continued only if the benefit-risk 
profile remains favourable (WHO, 2005). This makes risk-benefits analysis for evaluating clinical 
trial benefits very important.  
 
The data monitoring committees (DMCs) or data and safety monitoring boards (DSMB) play a 
critical role in the conduct of clinical trials by assessing the risks and benefits of an intervention 
as data accumulate (DeMets and Ellenberg, 2016). Monitoring by the DMCs is motivated 
primarily by an ethical imperative to prevent dangerous outcomes by stopping the trial early or 
to make the superior treatment available as soon as the evidence is definitive (DeMets and 
Ellenberg, 2016). Numerous complex statistical methods are used to assess the progress, success 
or failure of the trial. This is done by comparing the test group results with the placebo group and 
using the differences to make an assessment (Chow and Liu, 2008).  
 
The is however, documented absence of clear criteria for assessing the risk-benefit ratio  and this 
is a weakness in the IRB review process with some members of the IRB having been shown to not 
be fully competent in carrying out such evaluations (Van Luijn et al., 2007). In order for a study 
to be approved by the IRB, the risk-benefit ratio must, in the IRB's opinion, be favorable, in 
balance, or proportional (Van Luijn et al., 2007). This assumes that IRBs are sufficiently aware of 
which risks the medical research community and society, in general, find acceptable in relation 
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to which benefits (Van Luijn et al., 2007). The extent to which this assumption is justified in 
practice is open to question, especially considering the vague description of this requirement in 




Studies have shown inadequacies in how some clinical trials are conducted, managed and 
reported (Umscheid et al., 2011; Smyth et al., 2015). A sound scientific basis and a well-structured 
protocol can answer clinical questions but in the presence of inept management, successful 
delivery of a trial is unlikely (Farrell et al., 2010; Goodarzynejad and Babamahmoodi, 2015). Once 
an intervention is approved, a phase IV trial should be conducted to evaluate adverse reactions 
and effectiveness when administered to the general population (Umscheid et al., 2011). The 
literature suggests that less than half of such studies are actually completed or even initiated 
(Umscheid et al., 2011) 
 
There is an agreement in literature that the approach to running clinical trials requires an 
approach reform (Macleod et al., 2014; Borgerson, 2016; Ioannidis, 2016). This thinking follows 
the continuous improvement philosophy which promotes on-going improvements that involves 
everyone in the organization and on all fronts (Thorp, 1999; Sapountzis, 2013). There are those 
who have recommended the application of project management in clinical research (Siegfried et 
al., 2010; Payne et al., 2011; Aghayan et al., 2014; Goodarzynejad and Babamahmoodi, 2015). 
Payne et al. (2011) insisted that the use of project management increases the effectiveness of 
health and medical research projects as well as communication and teamwork within those 
projects. There also those who are specifically proposing development of a value culture in 
clinical research by integrating benefits with performance management and managing benefits 
from a portfolio perspective (Mossalam and Arafa, 2016). An integrated management model that 
merged existing project management and benefits management processes has been shown to 
increase the likelihood of projects achieving organisational goals, both in relation to IT and 
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general investments (Ward et al., 1996; Lin and Pervan, 2003; Ward and Daniel, 2006; Mihić et 
al., 2012; Breese et al., 2015; Serra and Kunc, 2015; Mossalam and Arafa, 2016).  
 
Clinical trials are intricately detailed and complex projects that need to be completed according 
to stringent global regulations and standards, and for a trial to be effective, multiple skill sets and 
strong hands-on management are essential (Bairu and Chin, 2012). There is a clear need for 
changes in the management approach of clinical trials to not only deal with increasing complexity 
and limitations, but also to improve the chances of clinical trials benefits realization. It is 
important for clinical trial management to adopt BRM “mentality” that focuses on factors that 
are required to realize the benefits from the projects (Breese, 2012; Chih and Zwikael, 2015). 
 
Keeping in mind that Shenhar and Dvir (2007) pointed out that  the ‘one size fits all’ approach to 
managing projects was not universally successful, the recommended management reforms in 
this study are not failproof but are believed to increase the odd of benefits realization. 
Koonrungsesomboon et al. (2016) highlighted that there is a need for a structured approach for 
assessing the clinical promise of new interventions. The first obvious limitation of benefits 
management in HIV clinical trials is that there were no documented processes, at least as far as 
this study could establish. Once the formal incorporation of BRM is adopted in clinical trials, it is 
important to ensure that these are visible to all those that are involved in the management of 
clinical trials. This will improve the understanding and/or awareness of the processes and 
therefore enable their implementation. HIV clinical trials should maybe adopt the practice of 
having a benefits champion that is used in IT/IS. This approach spreads out the BRM 
accountability per benefit to several people to enable benefits follow up and sustainability. The 
IRBs and DMCs/DSMBs should also have an increased role in benefits management (Umscheid et 
al., 2011). 
 
From 1999 to 2005, the total procedures per trial protocol increased by 65 percent, with unique 
procedures per trial protocol increasing by 46 percent (Bairu and Chin, 2012). The findings from 
this study, have led to the proposal of some key protocol adjustments.  One such proposal is to 
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adjust the adjusting the 12 golden rules of GCP by including application of benefits management 
as one of the rules. The CONSORT and SPIRIT statements as well as how clinical trials are reported 
is also another proposed adjustment. When organizations embrace changes in their business 




As a relatively experienced life scientist with some understanding of how clinical trials work, 
incorporating management techniques to improve outcomes of clinical trials would be an 
essential undertaking. This work is no way comprehensive enough to draw very strong 
conclusions or propose massive process changes in clinical trials. It can however be used as a 
basis for a more comprehensive and unrestricted study into potential applications of BRM in 
clinical trials. Mossalam and Arafa (2016) proposed a benefits realization management process 
compatible with the process groups of the Project Management Institute (PMI) body of 
knowledge which will enable organizations to cascade responsibilities of delivering values to the 
project manager level. To activate this concept, a strong governance system should be in place 
to manage benefits effectively (Mossalam and Arafa, 2016).   
 
BRM is a key aspect of project management that can possibly improve the delivery of the clinical 
trial promise. At the moment, this study showed that BRM in not a distinct or formal practice in 
clinical trials management although aspects of benefits management exist in current clinical trial 
processes. An immediate recommendation would be an assessment of the effects of formally 
adding BRM practices to clinical trial management using a case study approach. This study simply 
complements existing literature that project management skills are needed in clinical trials and 
should be added to existing clinical trials management processes (Siegfried et al., 2010; Payne et 
al., 2011; Aghayan et al., 2014; Goodarzynejad and Babamahmoodi, 2015). The expectation 
would be that BRM processes improve the identification of clinical trial benefits, improve the 
execution of benefits realization plans while enabling continuous tracking of all clinical trial 
benefits during and well after the clinical trial. BRM will then contribute to increased chances of 
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achieving the clinical ethical requirements. Tracking the benefits will help keep the equipoise 
intact and with the principles of beneficence and maleficence in mind, benefits will then be 
maximized while possible harms are minimized.  
 
This work although basic and preliminary, could be used as a foundation to motivate increased 
BRM visibility and incorporation of BRM processes into in clinical trials management. This would 
improve the delivery of benefits ensure that no benefits are missed or mismanaged throughout 



































This chapter summarizes the more significant findings from this study. This chapter also points 
out the study limitations and makes recommendations for related future research. 
 
The main takeaway from this study was that BRM processes are not readily visible or documented 
in HIV clinical trials. The bulk of the focus in the guideline about management of clinical trials 
appeared to be on human safety and risks of clinical trials which results in reduced prioritization 
on management of benefits. Recent growth in the clinical trial industry and the increasing 
complexity of clinical trials, warrants adjustments to the approach. This study proposes a more 
formal BRM approach to HIV clinical trials from the start of the clinical trial until some significant 
time after the clinical trial has been closed off.  
 
The current state of general management in clinical trials can ease the introduction of BRM into 
clinical trials. The management approach is already orientated toward both deliverables and 
value. Most of the people involved in management are included in strategizing and are highly 
confident in that clinical trials deliver their promises. The established need for improvement can 
be addressed by incorporating and promoting application of formal BRM processes. Current 
clinical trial processes that are used to set and evaluate endpoints, apply interim analysis 
methods and assure beneficence, should be  incorporated into formal BRM processes in a similar 
way to what was proposed by Mossalam and Arafa (2016). Other approaches used in other 
industries that should be adopted include the allocation of benefits realization responsibilities 
and starting with the end in mind.  
 
Undoubtedly, there are better ways in which the literature and guidelines review could have 
been conducted. The search for keywords that are relate to BRM in clinical trials documents can 
be improved. Computational logarithms would probably be more efficient with such searches. 
The ability to execute some of these searches was beyond the skills level of the researcher. The 
search was manual with basic in-document program searches of only documents known to exist 
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by the researcher and also accessible to the researcher. One other limitation with the review was 
that some of guidelines were worded in formal law terminology that could have been missed by 
the researcher. The response rate to the survey was very low and this forced a change in the 
focus group. As a way to narrow down the sampling and easy access to some clinical trials 
managers, this study originally considered focusing only on HVTN trials, but some people 
contacted to participate in the survey indicated that were uneasy responding without the 
approval of the HVTN leadership, if at all. The study was therefore forced to widen the search for 
respondents to all those who are part of any HIV clinical trial. There was also a possibility some 
of the responses may have been tainted by bias as some of the people who currently manage 
clinical trials, would not want to appear incompetent or imply that their work was futile. This 
limitation could be addressed by further widening the type of clinical trials to all clinical trials as 
a way to get a more comprehensive respondents’ analysis.  
 
A potential worthwhile future study could be that of a long-term nature looking into the potential 
effects of BRM processes on clinical trials. An alternative future study could adopt the case study 
approach where several people who are manage clinical trials are trained in benefits realization, 
given a chance to apply the BRM processes over time and the impact assessed. If the impact of 
BRM in other industries is anything to go by, there is a chance that formally incorporating BRM 
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8 Appendix A 
 
Table 7 Schools of thought of research 
 Positivism Post-positivism Interpretivism Critical theory 
Ontology Static and fixed, 
overarching 
objective truth 




changing; No one 
ultimate truth 





knowledge can be 
neutral or value 
free    
Objective,  
world is not fully 
accessible,  





one ultimate or 













method to develop 
abstract laws to 
describe and 
predict patterns, 






























Research is used to 
envision how things 
could change 














statistical testing of 
hypotheses 
Quantitative and 




















9 Appendix B 
The Questionnaire 
 
Ø Thank you for agreeing to respond to this questionnaire.  
Ø The purpose of this research is to explore project management processes used in managing 
clinical trials with specific focus on benefits realization management (BRM). This will be done by 
reviewing documented guidelines on running and managing clinical trials as well as online surveys 
with individuals involved in the management of clinical trials.  
Ø Please note that you will remain completely anonymous and your responses will be kept strictly 
confidential.  You are free to withdraw from the process at any time.  
 
1. Were you as (principal investigator/trial manager/project manager/clinical trial 
coordinator/other) involved at the strategic and planning level of clinical trial? 
 
2. What would you say is the current management approach of clinical trials? 
A- Output-focused (deliverables and efficiency-orientated)  
B- Outcome-focused (benefits-value orientated)  
C- Both 
 
3. How familiar are you with Benefits Realization Management (BRM)? 
A- Never heard of it 
B- Familiar with it but I have not applied it in any project  
C- Familiar with it and apply it on all projects 
 
4. Are there comprehensive benefits management processes (Plan, Identify, Realize and 
Review) in HIV clinical trials? 
 
5. Using any number between 1-5 (1 being the lowest and 5 the highest), where would you rank 
clinical trials BRM processes compared with those described in the literature:  
1 = Non-Existent 
2 = below   
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3 = same level 
4 = Above  
5 = Expert  
 
6. In your estimation, what percentage of clinical trials achieve what they set out to achieve? 
 
7. Who is accountable for realizing and sustaining clinical trial benefits?  
 
8. Is there a timescale by which individual benefits are expected to arise? 
 























Key Trial Activities   
 
At the beginning of a clinical trial, sponsors and investigators develop/formulate a feasible and 
scientifically valid set of important clinical/medical questions to be addressed by the intended 
clinical trial (Chow and Liu, 2008). Then the following steps are followed.  
 
1. Develop trial protocol  
• Sponsor and PI – risk identification, study design, control groups, statistical 
methodology  
2. Develop SOP  
• Sponsors – clinical investigation- IRB monitors: responsibilities, records, methods, 
standardized activities, monitoring and auditing  
3. Develop Support systems and tools  
• Brochure, logs, study flow sheets, computers  
4. Generate and receive trial documents approval  
• Finances, informed consent   
5. Select trial sites  
6. Ethics committee review and approval of Protocol (Prior to enrolment) 
7. Review by regulatory authorities  
• National/regional/local law and regulations  
8. Enrolment of subjects  
9. Handling of product to be tested  
10. Conduct the trial 
11. Safety management and reporting  
• Safety, adverse events, serious/life threatening unanticipated events  
12. Monitoring thee trial  
• Conduct, blinding, endpoints of the trial, risks, adherence to the protocol, data entry 
and quality control. 
13. Managing trial data  
• Make sure data are complete, reliable and processed right. 
14. Quality assurance of trial performance and data  
• Study monitoring  
• Data management  
• During and at completion  
15. Report the trial  
• Results described and summarized in study report (WHO, 2005). 
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11 Appendix D 
 
Format and Contents of a Clinical Trial Protocol (Chow and Liu, 2008) 





4. Study plan 
Study design 
Subject inclusion criteria 
Subject exclusion criteria 
Treatment plan 
5. Study drugs 
Dose and route 
Method of dispensing 
Method and time of administration 
Description of controls 
Methods of randomization and blinding 
Package and labeling 
Duration of treatment 
Concomitant medications 
Concomitant procedures 
6. Measurements and observations 
Efficacy endpoints 
Safety endpoints 
Validity of measurements 
Time and events schedules 
Screening, baseline, treatment periods, and post-treatment follow-up 
7. Statistical methods 
Database management procedures 
Methods to minimize bias 
104 
 
Sample size determination 
Statistical general considerations 
Randomization and blinding 
Dropouts, premature termination, and missing data 





Statistical analysis of demography and baseline characteristics 
Statistical analysis of efficacy data 
Statistical analysis of safety data 
8. Adverse events 
Serious adverse events 
Adverse events attributions 
Adverse event intensity 
Adverse event reporting 
Laboratory test abnormalities 
9. Warning and precautions 
10. Subject withdrawal and discontinuation 
Subject withdrawal 
End of treatment 
End of study 




12. Institutional review and consent requirements 
Institutional review board (IRB) 
Informed consent 
13. Obligations of investigators and Administrative aspects 
Study drug accountability 
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Case report forms 




Form FDA 1572 
Signatures of investigators 
Confidentiality 
Publication of results 




































Benefits Realization in Clinical Trials Study  
(Consent Form) 
 
The study explores project management processes used in managing HIV clinical trials with specific focus 
on benefits realization management (BRM). This study will establish awareness and application BRM 
frameworks within the HIV clinical trials as proposed in literature through semi-structured assessment of 
individuals involved in the management of clinical trials. The findings from this study will help in the 
improvement of BRM processes in clinical trials or serve as a guideline on how BRM can be incorporated 
into current management practices of clinical trials. This project is run by a master’s student registered at 
the University of Cape Town.  The student would like to ask you some questions to establish the existence 
and possible effectiveness of benefits management processes in HIV clinical trials. 
 
Before responding, the student wants to make sure you understand the following information about the 
study: 
• Your participation is entirely voluntary. You may refuse to take part in the questionnaire, and you may 
stop at any time if you do not want to continue. You also have the right to skip any particular question 
or questions if you do not wish to answer them. 
• The time it takes to complete the questionnaire will vary depending on how many sections of the 
questionnaire are relevant to you, but the average amount of time is about 8 minutes. 
• You have the right to ask questions at any point before or during the responding  
• All information collected for this study will be kept strictly confidential. While the data collected will 
be used for research purposes, information that could identify you or your household will never be 
publicly released in any research report or publication. 
• Your personal details will only be kept on record for instances whereby additional information may 
be required. However, we will ask your permission to participate in the survey again each time. 
Agreeing to participate now does not mean you have to participate in future surveys. 
 
By signing below, you signify that you agree to participate in the study, and that your participation is 
entirely voluntary. 
 
_____________________                                                                                   _____________________ 
SIGNATURE: Participant                                                                                       DATE 
 
 
_____________________                                                                                   _____________________ 
SIGNATURE: Student                                                                                            DATE 
 
 
If you have questions about this study or the research project you can call Molati Nonyane 071 887 0438 
or molati.nonyane@gmail.com. This study has been reviewed and approved by the ethical review 
committee of the University of Cape Town (pending). 
 
 
